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ABSTRACT OF THE DISSERTATION 
 
Mechanisms of induction and maintenance of Ptgs2 in colonic mesenchymal stem cells 
 
by 
 
Monica Rae Drylewicz 
 
Doctor of Philosophy in Biology and Biomedical Sciences 
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Professor Thaddeus Stappenbeck, Chairperson 
 
 
Colonic injury and inflammation exhibit high morbidity and mortality in western 
society and are increasingly diagnosed in human patients.  In many models of such 
gastrointestinal insults, prostaglandin endoperoxide synthetase 2 (Ptgs2; cyclooxygenase 
2) and its downstream synthetic products, most notably prostaglandin E2, support 
proliferation and modulate the inflammatory immune response, two functions involved in 
proper injury response.  We identified a primary source of this mediator as a population 
of stromal cells constitutively expressing Ptgs2 that appear to be required in two different 
model injury systems: administration of dextran sodium sulfate (DSS) and colonic biopsy. 
The central role of Ptgs2-expressing cells in injury demonstrates the importance of 
understanding Ptgs2 regulation.  We therefore created a robust in vitro system for 
studying the pathways and molecules involved by isolation of Ptgs2-expressing colonic 
stromal cells and identified the isolated lines as colonic mesenchymal stem cells (cMSCs).  
We then demonstrated the dominance of post-transcriptional regulation of Ptgs2 
expression in cMSCs.  Subsequent global gene array analysis comparing these cMSCs to 
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a similar cell isolated from the bone marrow revealed a number of candidate genes with 
potential roles in post-transcriptional regulation of Ptgs2 expression. 
We determined that Fgf9 can regulate Ptgs2 through Fgf receptor expressed 
preferentially in cMSCs.  Downstream of Fgf9, phosphorylation of Erk and increased 
abundance of mRNA binding protein CUGbp2 augments Ptgs2 expression. Furthermore, 
Fgf9 expression in the adult colonic epithelium ideally positions this growth factor to 
affect Ptgs2 expression in vivo.  We also found that loss of insulin growth factor 2 
binding protein 1 (Igf2bp1 or Imp1) results in a decrease in Ptgs2 and confirmed the 
ability of Imp1 protein and Ptgs2 mRNA to interact in the cellular environment.  
Additionally, we discovered increased Imp1 expression in the colonic biopsy wound bed 
compared to normal mucosa and co-localization of Imp1 in wound bed Ptgs2-expressing 
cells. 
Overall, this work has uncovered multiple mechanisms involved in the complex post-
transcriptional regulation of Ptgs2 in isolated stromal cells and demonstrated the role of 
these pathways in response to multiple forms of colonic injury.
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CHAPTER 1: INTRODUCTION 
 
Ptgs2 Expression and Regulation in Colonic Injury 
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Chapter 1: Introduction 
A variety of injurious insults to the colon are seen in human patients from cancer 
lesions to chronic inflammation to parasitic infections with many detrimental sequelae.  
The cost in mortality and in morbidity is high.  Understanding the mechanisms resulting 
in various injuries and the mechanisms involved in resolving these injuries could create 
better diagnosis and prognosis methodologies and more effective, targeted treatment for 
specific situations.  We and others have recognized the important role of prostaglandin 
endoperoxide synthetase 2 (Ptgs2) and its downstream synthetic products, prostaglandins, 
in mediating responses to injury via regulation of proliferation and modulation of the 
immune system.  A precise knowledge of the regulation of this gene is therefore 
necessary to fully understand, develop, and evaluate interventions in colonic injury in 
human medicine. 
Biology and histology of the colon 
The colon of the mouse, a model of the human organ, is a tubular organ consisting of 
various layers of cellular tissues. The inner most layer, abutting an inner lumen 
containing an abundant microbial population, is simple columnar epithelium and the 
surrounding mesenchyme that together make up the mucosa.  Beyond this layer, located 
radially are the muscularis mucosa, submucosa, muscularis propria made up of circular 
and longitudinal layers, and outer serosa.  The enteric nervous system runs the length of 
the colon with the muscularis.  The colon can also be divided from proximal to distal: 
ascending colon, transverse colon, descending colon, and finally the rectum. 
The inner epithelium of the colon serves an indispensable barrier function separating 
the host organism and the microbial contents of the colonic lumen.  This barrier allows 
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the lumenal bacteria and host to exist symbiotically rather than antagonistically.  The 
colonic epithelium is made up of many invaginations along the length of the organ called 
the crypts of Lieberkuhn.  These crypts contain the epithelial stem cell putatively at the 
base, colonic epithelial progenitors (ColEPs), and the three mature epithelial cell types: 
absorptive enterocytes, secretory goblet cells, and enteroendocrine cells.  The ColEPs are 
also referred to as transit amplifying cells which rapidly proliferate and provide the 
epithelium with a constant supply of maturing cells. 
Surrounding these crypts are many cells which collectively make up the colonic 
mesenchyme and support the epithelium.  The area most closely associated with the 
proliferative/stem cell compartment is often referred to as the stem cell niche as it is at 
least partially responsible for the support, maintenance, and regulation of the stem cell1.  
The most abundant cell types in the mesenchyme are myofibroblasts, endothelial cells, 
macrophages, and dendritic cells.  Other populations are also represented including 
colonic stromal cells expressing Ptgs2, B cells, T cells, plasma cells, and dendritic 
processes of the enteric nervous system.  Many different signaling pathways operate in 
the regulation of epithelial organization and differentiation2,3.  For example, the Wnt 
pathway is highly active in the lower crypt where the ColEPs are constantly undergoing 
division to supply the rest of the epithelium.  The role of the Wnt pathway has been well 
illustrated by a number of studies.  Neonatally, deficiency of Tcf4, the transcription factor 
activated by canonical Wnt stimulation, results in an endoderm made up purely of 
differentiated epithelial cells and devoid of a proliferative compartment4.  Likewise, in 
the adult, targeted expression of the Wnt inhibitor dickkopf-1 leads to a vast decrease in 
epithelial proliferation and apparent loss of crypts5.  Suggestive of a role in inhibiting 
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proliferation and/or inducing differentiation, TGF-β and the type II TGF-β receptor are 
both localized in the upper epithelial compartment.6  The activity of bone morphogenetic 
proteins seems to be similar to that of its family member TGF-β as demonstrated by an 
association between its loss-of-function and dysregulated proliferation shown by high 
rates of polyposis3.  The Notch and Hedgehog signaling pathways seem to function 
primarily in cell fate decisions.  Animals deficient in Notch signaling (via loss of HES-1) 
lose absorptive cells while expanding the secretory compartment containing goblet cells 
and enteroendocrine cells7.  Further downstream of Notch, Neurogenin 3 is suggested to 
be responsible specifically for the enteroendocrine lineage8.  Sonic hedgehog is expressed 
only at very low mRNA levels in the base of the crypts.  It seems to be more involved in 
patterning the radial aspects of the intestine9.  Indian hedgehog is expressed in 
differentiated colonic enterocytes and thus hints at a possible role in differentiation of 
these cells.  Indeed, blockade of the hedgehog pathway in general by cyclopamine-
mediated inhibition of Smoothened leads to increased proliferation of the epithelium10. 
These various signaling pathways control homeostasis in the colon which can be 
simplistically viewed as directing proliferation toward the base of the crypt and 
differentiation toward the cuff.  Various injuries, discussed below, place different stresses 
on the epithelium and often alter this delicate programming.  Combining knowledge of 
the basic biology of the normal colon along with responses during injury will increase the 
general ability of medicine to treat and heal these insults. 
Models of colonic injury 
A variety of injury models have been developed and studied with the goal of 
understanding the mechanisms involved in the development and healing of inflammation, 
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injury, and cancer.  The primary interest of our lab has been focused on inflammatory and 
localized insults with the goal of forming a complete understanding of the mechanisms 
involved in the development and healing of colonic diseases in human patients.  Such 
knowledge may provide for improved diagnostic techniques and targeted treatments for 
many common colonic insults. 
Models of chronic inflammation 
A variety of colonic injury models for chronic inflammatory bowel disease have been 
developed over the past four decades11.  Many have been based on gene knockouts and 
transgenics of various immune genes such as IL-10.  Some models have been found by 
spontaneous development during breeding such as the C3H/HejBir.  Adoptive transfer of 
T cells has also resulted in colitis.  Many inducible models of colitis have been 
discovered as well through administration of various compounds/insults including 
dextran sodium sulfate (DSS), TNBS (2,4,6-trinitrobenzene sulfonic acid), indomethacin, 
iodoacetamide, acetic acid, oxazolone, peptidoglycan-polysaccharide, and radiation.  All 
of these models result in varying degrees of inflammation and ulceration of the 
epithelium, often accompanied by either or both a decrease in epithelial proliferation or 
an increase in epithelial apoptosis. 
One of the first reports rigorously documenting the injury induced by DSS was 
published in 199012.  Depending on the percentage of DSS given, the severity of colitis 
can be controlled.  Furthermore, the specific effects of the chemical on the colon are 
location dependent; for example, the transverse colon is more severely affected than the 
descending colon.  Our lab recognized the importance of another variable in this model: 
diet.  Mice fed a special diet intended for germ free animals during DSS administration 
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are less susceptible to the effects of the chemical compound13.  As mentioned, due to 
proximal-to-distal variations, the location of injury analysis must be strictly distinguished.  
In our model, administration of DSS does not apparently affect the ascending colon or the 
majority of the descending colon in WT mice.  The transverse colon is afflicted with a 
number of smaller ulcerations surrounded by hyperproliferative crypts while the distal 
rectum simply shows ulceration.  Our lab has also discovered that DSS-treated Myd88-/- 
and Ptgs2-/- mice lose epithelial proliferation in rectal crypts that can be rescued by 
administration of prostaglandin E2 (PGE2) during DSS administration14.  By analyzing 
this model with the goal of identifying the cellular source of PGE2, we discovered a 
population of cells in the mesenchyme that constitutively express prostaglandin 
endoperoxide synthase 2 (Ptgs2 or cox-2).  During DSS injury, these cells redistribute to 
the epithelial stem cell niche, the mesenchyme apposed to the base of the colonic crypts, 
seemingly to maintain proliferation of the stem cell compartment.  As shown herein, 
isolation of colonic stromal cells was accomplished, and these cell lines allowed rigorous 
examination of the mechanisms involved in Ptgs2 regulation.  We show that Ptgs2 
regulation can be mediated by Fgf9 signaling through Erk activation and CUGbp2 
stabilization. 
Model of physical injury 
Our laboratory has pioneered the development and study of a new model of localized 
physical colonic injury that allows localization and precise timing of injury to be 
specifically studied.  This model is the colonic biopsy model15.  In this model, a portion 
of the mucosa of the colon is removed by biopsy and the injury is followed over time by 
endoscope until sacrifice of the mice followed by gene expression and histological 
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studies.  It has been demonstrated that the healing of these wounds is predictable and 
occurs over approximately 6-8 days depending on the size of the wound15 (unpublished, 
H. Miyoshi and N. Manieri).  Histology and cytokine expression were also found to be 
predictably reproducible.  The wound bed, consisting of granulation tissue, is rapidly 
covered by a single cell epithelial layer.  It was found that proper expression of IL-13 and 
IL-4 was required for timely and organized wound healing. 
An understanding of the mechanisms underlying wound healing will lead to a better 
overall picture of how the colon reacts in injury and will identify the molecules most 
important in healing.  It is demonstrated herein that one of these molecules is Ptgs2 and 
that its regulation in this case is likely partially mediated by a novel trans-acting factor, 
insulin growth factor 2 binding protein 1 (Igf2bp1 or Imp1). 
Biology of Ptgs2 
Ptgs2 is one of the two rate-limiting catalysts in the synthesis pathway of 
prostaglandins (PG) and thromboxane (TX).  These enzymes catalyze the oxygenation of 
arachidonic acid to prostaglandin H2 which is further converted by specific PG and TX 
synthases to PGI2, PGE2, PGF2, PGD2, and TXA216.  In general, Ptgs1 is considered to 
have housekeeping and homeostatic functions while Ptgs2 is considered to be the 
inducible form upregulated primarily in inflammation. 
The Ptgs2 knockout mouse was generated in 1995 and analyzed17-19.  The primary 
phenotype of an unperturbed Ptgs2 KO mouse is renal dysplasia with some cardiac 
fibrosis, and females are infertile.  In the absence of an injurious insult, the colon is 
normal by all measurable aspects in a Ptgs2 KO mouse.  However, upon injury, Ptgs2 is 
required for proper response both in radiation injury20 and DSS-mediated injury14,21.  
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These studies also demonstrated the ability of PGE2 to rescue the observed phenotypes, 
strongly suggesting that Ptgs2 was necessary due to its synthetic function upstream of the 
secretion of PGE2. 
PGE2 signals through four different G-coupled protein receptors termed EP1-4.  
These receptors are expressed in various cells throughout the gastrointestinal (GI) tract22 
and seem to have a role in a variety of basic GI functions including gastric acid, sodium 
bicarbonate, and mucus secretion, motility, and cytoprotection.  The most important of 
the four receptors in cytoprotection against DSS-induced colitis is EP4 as demonstrated 
by the severity of injury in mice lacking EP4 or treated with an EP4 antagonist23.  The 
expression of the EP4 receptor by crypt epithelial cells further suggests the importance of 
this receptor in responding to DSS injury.  Intriguingly, a genome wide association study 
recently identified a SNP located in the EP4 gene as a risk factor in the inflammatory 
condition Crohn’s disease24.  As mentioned, our lab has described the role of Ptgs2 and 
subsequent PGE2 in maintaining epithelial proliferation in DSS injury14.  It appears that 
EP4 is the receptor important in this pathway. 
Though normally considered to be expressed upon induction, Ptgs2 is expressed 
constitutively in certain cells, a fact that has been recognized in the small25 and large14  
intestine.  Taking together the developmental problems and injury response deficiencies 
of the Ptgs2-/- mouse and the constitutive expression of Ptgs2 in some, albeit rare, cells, it 
seems that a better understanding of the regulation of Ptgs2 is necessary to a complete 
understanding of homeostasis and healing. 
The regulation of Ptgs2 is complex and involves many transcriptional and post-
transcriptional mechanisms26,27.  Regulation at the transcriptional level has been highly 
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studied, especially in terms of upregulation during inflammation.  Less well-studied is the 
post-transcriptional regulation of Ptgs2 as well as recognition of the constitutive 
expression of this gene in adult tissues.  Creation of a lacZ Ptgs2 reporter mouse clearly 
demonstrated the expression of Ptgs2 in adult tissues in the mammal in the absence of 
inflammatory insult28 with the greatest expression in the colon and the testis.  Many 
growth factors normally present in various tissues of an adult animal have been 
implicated in at least partial control of Ptgs2 expression level including EGF29, 
PDGF30 ,basic Fgf31 ,and TGFβ32 . In these investigations, these factors were 
demonstrated to act through Src and various MAP kinase pathways. 
We and others have noted that Ptgs2 is very strongly regulated at the post-
transcriptional level.  The area of focus of many investigations is the 3’ untranslated 
region (UTR) of the Ptgs2 mRNA transcript.  This region contains multiple AUUUA 
sequences also known as AREs or AU-rich element33,34.  This sequence is known to be 
targeted by multiple mRNA binding proteins that, while stabilizing the mRNA, have 
varying and sometimes unclear effects on translation of the transcript.  One well-
recognized binder of AREs and regulator of Ptgs2 is CUGbp2 (CUG triplet binding 
protein35) which is reported to stabilize the transcript and decrease translation36.  
Interestingly, binding to the ARE is degenerate and the identity of the binding proteins 
seems dependent on the physiologic conditions.  For example, CUGbp2 and HuR can 
both bind Ptgs2 but CUGbp2 decreases while HuR increases translation.  Following 
radiation injury, the CUGbp2 abundance increases and may be able to out-compete HuR 
binding, thus decreasing Ptgs2 translation37,38.  It has also been shown that the binding of 
trans-acting factors can be affected by more than just expression level.  Phosphorylation 
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of CUGbp2 by Src is capable of increasing binding affinity of the protein for Ptgs2 
mRNA30.  Thus the post-transcriptional regulation of AREs is complex and dynamic; 
however, the degenerate nature of this binding sequence that is found in a great 
abundance of mRNA transcripts suggests that in order to specifically regulate Ptgs2, 
there must be further mechanisms involved. In order to study these mechanisms in more 
detail within this thesis, we employed a cell culture line of colonic stromal cells that 
constitutively express Ptgs2. 
Mesenchymal Stem Cells 
This work uses isolated colonic stromal cells that constitutively express high levels of 
Ptgs2 as a primary tool to investigate the regulation of Ptgs2.  Herein we identify these 
cells as mesenchymal stem cells (MSCs, also known as multipotent stromal cells), a cell 
type found in virtually all tissues39 and capable of differentiating into multiple 
mesenchymal lineages.  MSCs were originally recognized and isolated in 1974 by 
Friedenstein from the bone marrow40.  These cells were isolated simply by plastic 
adherence and showed a fibroblastic morphology.   In fact, the cells were originally 
termed “precursors to fibroblasts” due to their morphological features and simultaneously 
of their relatively undifferentiated state.  The terminology of “mesenchymal stem cell” 
surfaced later as it was recognized that these cells could undergo differentiation into a 
variety of different mesenchymal cell types including chondrocytes, osteoblasts, 
adipocytes41,42, and myocytes43.  This multipotency in vitro remains the gold standard for 
the definition of MSC though more criteria have been proposed including the expression 
of certain surface markers44. 
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In addition to their stem cell-like abilities, MSCs retain a number of other properties 
that can be generally categorized as ‘signaling functions’.  They have been shown to 
modulate the immune system in vitro in a number of different assays, generally inducing 
a more tolerant or anti-inflammatory phenotype in different immune effector cells.  
Aggarwal and Pittenger demonstrated the ability of MSCs to decrease TNFα and increase 
IL-10 secretion by dendritic cells, inhibit Th1 and NK cell IFNγ secretion, and increase 
Th2 IL-4 secretion.  They also showed MSC ability to increase the number of T 
regulatory cells45.  Modulation of the immune system seems to be a necessary function 
for the beneficial effects of MSCs46.  The precise mechanism for these various effects has 
not been fully elucidated and probably cannot simply be attributed to one molecule or 
pathway within MSCs.  The mechanism(s) likely varies from one cellular interaction to 
the next.  Many soluble secreted factors have been implicated including PGE247, 
hepatocyte growth factor, TGF-β, indoleamine 2,3-dioxygenase, nitric oxide, IL-1048, 
heme oxygenase 149, and IL-650.  Most of these were first determined by in vitro studies.  
More recently, other molecules have been identified including an IL1R antagonist51 in 
vivo.  Indeed, even contact-dependent mechanisms have been proposed, adding to the 
very complex mechanisms involved in the various functions of MSCs52,53.  While the 
effects of MSCs on the immune system in vitro are well-accepted, there remains some 
debate on the relevance and strength of similar interactions in vivo54,55.  One study even 
suggests that the effect of MSCs on T cells remains limited to their proliferation and do 
not affect effector function as measured by upregulation of activation markers and 
cytotoxic assay56. 
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Stimulation or recognition of signaling molecules and cytokines have been proposed 
to affect MSC immune modulation properties.  TNFα and IFNγ are able to increase 
secretion of various immune modulators by MSCs57,58.  Expression of TLRs has been 
evaluated in MSCs as well and proposed to affect function59,60.  Also acting in their 
capacity as signaling cells, MSCs have been implicated in promoting cancerous 
conditions, especially metastasis.  Recently it has been demonstrated that coculture with 
MSCs increases the metastatic capability of breast cancer cells dependent on the secretion 
of CCL5 by MSCs61.  However, opposing viewpoints have also been published such as a 
model of hepatocarcinoma that is suppressed by interaction with MSCs62.  The precise 
role of MSCs in cancer may vary on a case by case basis63. 
MSCs have become a very hot topic in recent years as a result of their recognized 
immune modulation and tissue regenerating abilities64.  The natural source of MSCs 
during development is currently under investigation with evidence that they originate as 
perivascular cells65.  However, MSCs derived from bone marrow have been employed 
therapeutically in cardiac ischemia models66, kidney ischemia and drug-induced injury 
models67, colitis models68, gastric ulcer models69, nervous system injury models70, and 
tendon regeneration models71.  MSCs are even currently being used in human clinical 
trials.  Osiris Therapeutics Inc is enrolling patients for Phase III trials for treatment of 
Graft-vs.-Host Disease and Crohn’s Disease and for Phase I trials for acute myocardial 
infarction with the drug Prochymal, an intravenous infusion of ex vivo-expanded bone 
marrow-derived MSCs72.  Naturally, trafficking of such cells through the endothelium 
has come under intense investigation in order to better understand migration and homing 
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of these cells in the body73.  Some of the currently proposed players include VCAM, β1 
integrins, MMP-2, various cytokines73, and SDF-166,70. 
The vast majority of investigations involving MSCs are centered on those derived 
from bone marrow.  However, MSCs, as mentioned above, can be isolated from virtually 
every organ in the body39 and demonstrate small differences in their various properties74.  
Each organ-specific MSC is unique though all hold to the same definition of 
multipotency.  The field continues to suffer from a lack of a precise marker for this cell 
type.  The most consistent two markers appear to be CD29 and CD4439 but these are 
highly non-specific.  Different investigations have profiled MSCs in various manners but 
have yet to identify a precise marker.  Microarray analysis of expanding and 
differentiating bmMSCs demonstrated that expansion in vitro does not significantly alter 
expression profiles75.  Others have attempted to uncover a specific marker76 but such 
studies have not proven beneficial to future applications.  Cytokine and stem cell 
molecular profiles comparing the most commonly employed MSCs, those derived from 
adipose and bone marrow, concluded that differences between these two types were 
minimal77.  Identification of a specific marker could greatly aid future studies of MSCs. 
Insulin growth factor 2 binding protein 1 (Igf2bp1, Imp1) 
This work provides evidence of regulation of Ptgs2 post-transcriptionally by Igf2bp1 
or Imp1, an interaction that has never before been recognized.  A widely-known mRNA 
binding protein, Imp1 is a highly conserved 577 amino acid protein made up of two RRM 
(RNA recognition motif) domains at the N terminus and four KH (hnRNP K homology) 
domains at the C terminus (Fig 1.1).  In fact, the primary protein sequence in humans and 
in mice differs by only 4 amino acids.  Imp1 has been reported to bind up to 3% of the 
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transcriptome in one cell line78 primarily in predictably sized ribonucleoprotein 
complexes.  The binding sequence of Imp1 targets is not fully characterized and appears 
to be degenerate and at least partially dependent on 3D structure of the mRNA molecule 
as well as on primary sequence79.  Due to its wide range of targets78,79, Imp1 has been 
studied in many different contexts and has been cloned and identified through multiple 
lines of investigation.  Its various functions are the focus of many continuing studies. 
 
Figure 1.1 
 
Figure 1.1  Depiction of Imp1 conserved protein domains. 
Conserved domains were found using the conserved domains search at NCBI.  
RRM is RNA recognition motif and KH is hnRNP K homology, both of which 
can interact with nucleotide sequences.  All binding activity has been reported to 
reside in the KH domains80.  Blue boxes, RRM; red boxes, KH. 
 
Identification of Imp1 
The gene termed Imp1 in humans was virtually simultaneously identified by multiple 
groups in multiple organisms in the mid 1990s81,82.  The laboratories of Singer83 and 
Yisraeli84 each identified the protein ZBP-1 or Vg1 RBP respectively as the factor 
responsible for localization of β-actin mRNA to the leading edge of fibroblasts in culture 
and specific for the so-called zip code binding sequence in its sequence.  Similarly, Vera 
was cloned as a binding protein for the vegetal localization element in Xenopus oocytes85.  
Yet another group interested in c-myc RNA stabilization identified CRD-BP (coding 
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region determinant binding protein) as a protein that stabilizes c-myc mRNA by binding 
within the coding region86.  The protein is also known as insulin growth factor 2 binding 
protein 1 (Igf2bp1) for its discovery by its ability to bind and regulate insulin growth 
factor II RNA87. 
Expression of Imp1 
Imp1 is broadly referred to as an oncofetal protein in reference to its general 
expression pattern: it is found in the embryo, generally not in adult tissues, and again 
upregulated in various cancers.  In the mouse, Imp1 is expressed beginning at day 11.5, 
peaking at day 12.5, and dropping off rapidly thereafter in the whole embryo87.  These 
authors report expression most prominently at day 12.5 in the basal layer of the epidermis, 
in the skeletal muscle, and in trophoblasts of the placenta.  Another group finds 
expression by RT-PCR analysis in the distal intestine and strongly in the testis of adult 
animals.  They also find expression within the epithelium of villi by in situ 
hybridization88. 
Overexpression of Imp1 has been reported in a variety of cancers.  One report 
estimated that mesenchymally-derived tumors of all kinds showed increased expression 
of Imp1 in about 65% of cases89.  Later, the same group investigated tumors of the CNS 
(specifically brain) and non-small-cell lung carcinomas and noted 55% and 27% 
respective tumors that showed Imp1 misexpression90.  Most intriguing from the 
perspective of our lab, Ross et al91 found that up to 81% of colorectal carcinomas express 
Imp1 as measured by RT-PCR.  Also, a subject of recent focus, Imp1 has been found to 
be overexpressed in 60% of breast carcinomas92 and in malignant melanoma93. 
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The precise functions of Imp1 in development and in cancer progression are in 
various stages of understanding and remain the subject of investigation.  A complete 
knowledge of the various roles and functions of Imp1 may potentially show some 
promise in cancer diagnosis, prognosis, and treatment. 
Functions and regulation of Imp1 
As mentioned, Imp1 has been studied in many contexts from embryo polarization to 
translational repression.  Some of the most important are discussed here. 
A knockout mouse deficient in Imp1 has been produced by gene trap inserted 
between exons 2 and 3 and examined94 though, despite its being published 6 years ago, 
this initial report remains the only published study of this animal.  The Nielsen group 
documented increased perinatal mortality with 50% death within 3 days while those 
animals that survived were 40% smaller than litter mates throughout life.  The authors 
noted poor development of various organs with histological changes in the kidney and 
intestine.  They found small, hypoplastic glomeruli in the kidney and greatly decreased 
size of villi in the small intestine.  Furthermore, decreased cartilage was demonstrated by 
examination of the skeletons of mice.  These data indicate a necessary role for Imp1 in 
proper development.  Whether the need for Imp1 is purely embryonic could not be 
addressed by this experimental system and remains an important question: what is the 
role of Imp1 in the adult animal? 
As mentioned above, Imp1 is also known as CRD-BP, named for its affinity for the 
coding region of c-myc mRNA and its stabilization of this message in various in vitro 
systems.  The mechanism of stabilization of c-myc mRNA has been elucidated recently 
and may potentially prove similar in the case of Ptgs2 regulation.  An endonuclease 
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capable of cleaving c-myc mRNA within the coding region determinant was purified and 
shown to be inhibited from this degradative function in the presence of CRD-BP95.  
Subsequent studies identified a mechanism of activity of CRD-BP that may eventually 
prove to have broad applicability to the method of trans-acting factor stabilization of 
mRNA.  Specifically, Elcheva et al96 demonstrated that the destabilizing region mRNA of 
another target of CRD-BP (βTrCP1) is subject to degradation downstream of a specific 
micro RNA.  When CRD-BP is present, access to this coding region by the micro RNA is 
blocked which inhibits its ability to cause degradation of the mRNA transcript.  This 
suggests that the mechanism of stabilization is essentially steric hindrance by the 
presence of CRD-BP which blocks the function of proponents of degradation pathways. 
Another mechanism of Imp1 is alluded to by another name for the gene: zipcode 
binding protein 1.  It acts to localize RNA to the leading edge of fibroblasts, specifically 
β-actin mRNA.  There is strong evidence that an unphosphorylated version of ZBP-1 
binds to β-actin mRNA and this binding is lost upon Src-mediated phosphorylation of a 
specific tyrosine residue of ZBP-1.  Though stability of β-actin mRNA is increased by 
binding of ZBP-1, translation is decreased.  Upon release of the transcript purportedly by 
phosphorylation of the protein, the mRNA can then be translated into protein.  The 
authors speculate that this phosphorylation control allows for the buildup and localization 
of β-actin protein to the leading edge of cells97, but this remains to be rigorously 
demonstrated. 
Imp1 is also able to interact with multiple RNA transcripts unique to viruses.  One of 
these interactions involves the HIV protein Gag, a relationship that seems to decrease the 
infectivity of the viral particles98.  Here too, the binding interaction is mediated by the C-
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terminal KH domains of the protein, specifically the two most C-terminal iterations.  
Imp1 also interacts with the 5'UTR and 3'UTR of the hepatitis C virus, but in this case, 
the presence of Imp1 seems to enhance translation of the RNA99. 
The regulation of Imp1 itself has not been highly studied but has been touched on in 
an effort to understand the function of Imp1 overexpression in various cancers.  Noubissi 
et al100 found that Imp1 expression could be upregulated by activation of β-catenin/Tcf 
signaling.  Subsequently, a specific β-catenin element within the promoter of Imp1 was 
identified, and Imp1 protein was shown to interact with β-catenin mRNA and increase its 
stability, suggesting a coordinate regulation of the two genes101.  The same group has 
subsequently proposed evidence for prognostic ability of Imp1 in breast cancer 
metastasis102 though this remains in its infancy and will require specifically designed 
studies in order to fully address this hypothesis.  Essentially, the authors recognize that 
metastatic lines of breast cancer express lower levels of Imp1 and present evidence that 
within patient populations, in situ cancer cells express greater levels of Imp1 than 
metastatic cells; the expression of Imp1 in these cases can be at least partially mediated 
by β-catenin.  This observation raises the intriguing possibility of prognostic and 
interventional techniques based on employing Imp1 as a target. 
Summary 
The work described herein primarily focuses on increasing our understanding of the 
mechanisms of regulation of Ptgs2, an enzyme that is important in a variety of models for 
the proper response to and healing of colonic injury.  It seems that Ptgs2 likely acts on 
both proliferation of tissue as well as on modulation of the immune system and 
controlling the inflammatory response.  It is demonstrated that Ptgs2 is highly regulated 
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at the post-transcriptional level by various trans-acting factors: (1) CUGbp2 downstream 
of Fgf9 and Erk activation and (2) Imp1 through an as-yet uncharacterized pathway.  
Moving forward, clarification of the complex regulation of Ptgs2 may provide the ability 
to precisely manipulate this system in order to maximize healing and minimize morbidity 
in various human colonic injuries. 
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CHAPTER 2 
 
FGF9 Regulation of Ptgs2 Expression in Colonic Mesenchymal Stem Cells 
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Chapter 2: Abstract 
We previously found that a population of colonic stromal cells that constitutively 
express high levels of prostaglandin-endoperoxide synthase 2 (Ptgs2, also known as Cox-
2) altered their location in the lamina propria in response to injury in a Myd88-dependent 
manner.14  At the time of this study, the identity of these cells and the mechanism by 
which they expressed high levels of Ptgs2 were unknown. Here we found that these 
colonic stromal cells were mesenchymal stem cells (MSCs). These colonic MSCs 
expressed high Ptgs2 levels not through interaction with bacterial products, but instead as 
a consequence of mRNA stabilization downstream of fibroblast growth factor 9 (Fgf9), a 
growth factor that is constitutively expressed by the intestinal epithelium. This 
stabilization was mediated partially through a mechanism involving endogenous CUG 
binding protein 2 (CUGbp2). These studies suggest that Fgf9 is an important factor in the 
regulation of Ptgs2 in colonic MSCs and may be a factor involved in its constitutive 
expression in vivo.  
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Chapter 2: Introduction 
Homeostasis in the mammalian colon relies on proper function of the epithelium and 
underlying mucosal immune system. Both of these cellular components are challenged by 
a local environment of a robust and diverse array of microbes that normally reside in the 
lumen of the colon103-105.  An important feature of the epithelial barrier is that it 
undergoes constant renewal during the lifetime of the organism. This process can be 
enhanced in response to either infection or injury15,106.  Proliferative colonic epithelial 
progenitors (ColEPs) located in the basal one-third of the crypts of Lieberkühn are central 
players in the maintenance of the barrier epithelium in health and during injury 
response107.  ColEPs serve as a continuous source of maturing epithelial cells that migrate 
up crypts and terminally differentiate into one of three lineages: absorptive enterocytes, 
mucous-secreting goblet cells, and enteroendocrine cells. 
The source of the signals responsible for regulating ColEP proliferation and 
differentiation of their daughter cells both during homeostasis and in response to injury is 
the local microenvironment surrounding the crypt base termed the progenitor cell niche. 
This niche is partially composed of the surrounding mesenchyme1 that includes 
myofibroblasts, endothelial cells, neural cell extensions from the autonomic enteric 
nervous system, and mobile stromal cells capable of trafficking into and within the 
mesenchyme, such as immune cells13,108.  Signals released from these many varied cell 
types likely interact with each other and the epithelium to regulate ColEPs and their 
progeny in homeostasis and in response to injury.  
One additional cell type that we found appears to be an important component of the 
ColEP niche is Ptgs2-expressing stromal cells14. The key signaling molecule secreted by 
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these cells is one of Ptgs2’s downstream synthetic products: prostaglandin E2 (PGE2)14,16.  
The immune modulatory properties of this and other downstream products of this gene 
family (Ptgs1 and Ptgs2), have been well-established in vitro45. In the gut, PGs, most 
notably PGE2, have been shown to improve inflammation, ulceration, and other common 
measures of disease in model injury systems13,109-112. 
Our goal in the current studies was to define and identify these Ptgs2-expressing 
colonic stromal cells and determine the mechanism by which their expression of Ptgs2 is 
mediated. We identified Ptgs2-expressing stromal cells as consistent with tissue resident 
mesenchymal stem cells (MSC). We isolated colonic MSCs using previously established 
protocols39,40 and found that their properties further supported the hypothesis that the 
Ptgs2-expressing stromal cells were colonic MSCs. We found that the high level of Ptgs2 
expression in the colonic MSCs was not dependent upon exposure to bacterial products 
but rather to local growth factors, specifically Fgf9. We found that Fgf9 signaling was 
sufficient to maintain the high levels of Ptgs2 expression in cMSCs and that it appears to 
do so partially by Erk-mediated increase in mRNA binding protein CUGbp2 and 
subsequent stabilization of Ptgs2 mRNA. These studies suggest further the recognized 
role of various growth factors in stabilizing Ptgs2 mRNA and suggest part of the 
mechanism in play is constitutive, as opposed to induced, expression of this important 
enzyme. 
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Chapter 2: Materials and Methods 
Mice- All animal experiments were performed in accordance with approved protocols 
from the Washington University School of Medicine Animal Studies Committee. Mice 
involved in this study were housed in microisolator cages, in a specified pathogen-free 
barrier facility following a 12 hour light cycle and fed a standard irradiated chow diet 
(PicoLab Rodent Chow 20, Purina Mills) and water ad libitum. Ptgs2-/- mice19 were 
generated previously on a C57Bl/6 background. C57Bl/6 mice were obtained from the 
National Cancer Institute and C57Bl/6 germ free mice were obtained from Jeffrey 
Gordon (Washington University). 
Isolation of organ-specific MSCs- Lung, stomach, colon and bone marrow (flushed from 
isolated tibias and femurs) were removed from the mouse and were rinsed thoroughly 
with 1:1 HBSS:Dulbecco’s modified eagle’s medium (DMEM).  Each tissue was 
separately minced with scissors. The tissue fragments were placed in 20mls of 10mM 
HEPES-DMEM and 5µg/ml Type I collagenase (Gibco) and were incubated in an 
oscillating shaker at 225rpm at 37°C for 35min.  Dithiothreitol (Sigma) was then added to 
a final concentration of 20mM and incubation was continued for an additional 20min. 
The resulting cell suspension was filtered through a 70µm filter, pelleted at ~400g for 5 
min, washed once in complete media (low glucose DMEM with 10mM HEPES and 10% 
fetal bovine serum with penicillin/streptomycin), and plated on standard tissue culture 
plates (VWR) in complete media. Cells were cultured in a humidified chamber at 37°C 
and 5% CO2. After 1 hour, non-adherent cells were removed and adherent cells were 
maintained in culture, feeding every 3-4 days in complete media and were passaged (1:3) 
when they reached 90-100% confluence.  
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Isolation of bone marrow-derived macrophages- Bone marrow-derived macrophages 
were cultured by flushing femurs and tibias of mice and culturing the cell suspension in 
standard media supplemented with L-cell supernatant containing Csf-1113 for 7 days 
before replating and experimentation. 
Splenocyte proliferation assay- This assay was performed by isolation and activation of 
5x104 splenocytes in a 96-well dish by incubation with anti-CD3ε and anti-CD28 
antibodies114 in the presence or absence of cMSCs at a ratio of 5:1 – 50:1 
splenocytes:cMSC or in the presence of cMSC culture supernatant. Cells were incubated 
for 72hrs and pulsed with H3 thymidine. Plates were harvested and H3 thymidine 
measured. All conditions were performed in triplicate for each experiment. 
Manipulation of cell lines  To differentiate MSCs into adipocytes, isolated MSCs were 
treated with 10-8 dexamethasone and 5µg/ml insulin for 21 days41. Verification of lipid 
stores was done by staining with Oil Red O. To differentiate MSCs into osteocytes, 
MSCs were treated with 10-8 dexamethasone, 5µg/ml ascorbic acid 2-phosphate, 10mM 
β-glycerophosphate for 21 days41. Verification of Ca2+ deposits was performed by 
Alizarin Red S staining. 
LPS (Sigma) treatment of cells was carried out on cells plated at 105 cells/6-well dish 
well at a concentration of 1ng/ml to 100ng/ml. 
Serum starvation experiments were performed by slightly different methods based on 
specific application. Experiments were carried out on cells plated in 24-well or 6-well 
dishes using 5x104 cells/well or 1x105 cells/well respectively. For Fgf9 treatment, cells 
were starved for 2-3 hours in low glucose DMEM with 10mM HEPES before treatment 
with Fgf9 (Peprotech, 1 – 500ng/ml) for one hour before cells were lysed for RNA and 
 26
protein isolation. For transcriptional inhibition coupled with starvation, treatment with 
actinomycin D (4µg/ml, Sigma) was begun simultaneously with or without 250ng/ml 
Fgf9, and RNA was analyzed at 3hrs. For MEK inhibition, treatments with PD98059 
(100µM-300µM, Enzo Life Sciences) was performed in the same method as actinomycin 
D, and RNA and protein were collected at 3 hours. 
Prostaglandin E2 assay- Cells were cultured with or without LPS (1-100ng/ml; Sigma-
Aldrich) in 6-well plates at a density of 105 per well. Following 21-22 hour incubation, 
supernatants were collected for analysis using a PGE2 Elisa assay kit (Cayman Chemical) 
according to the manufacturer’s protocol. Cells were also counted and RNA isolated for 
qRT-PCR analysis. 
Cell transfection for shRNA treatment- HEK293T cells were transfected with Mission 
shRNA constructs specific for CUGbp2 and non-targeting control (CUGbp2 clones 
NM_010160.1-131s1c1, NM_010160.1-305s1c1; Sigma) and lentiviral packaging 
plasmids using FuGene HD reagent (Roche). Following one day transfection, cell media 
was refreshed and allowed to accumulate virus 24 hours. Viral-containing supernatant 
was used undiluted directly on plated cMSCs for 24 hours before adding puromycin 
(Sigma)-containing media for selection of positively infected cells. 
Quantitative RT-PCR analysis- Cells were treated as noted in various experiments before 
RNA isolation. RNA was isolated and purified using QiaShredders and a Qiagen RNEasy 
mini kit according to manufacturer’s protocol. cDNAs were synthesized using a 
Superscript III reverse transcriptase (Invitrogen), primed using random primers. 
Quantitative RT-PCRs were performed in triplicate for each sample using SYBR-green 
master mix (Clontech) and analyzed by either a Stratagene Mx3000P or Eppendorf 
 27
realplex Mastercycler.  The following primers were used: 18S 
(AACCCGTTGAACCCCATT, CCATCCAATCGGTAGTAGCG); Ptgs2 
(TGCCTGGTCTGATGATGTATG, GCCCTTCACGTTATTGCAGATG); Human Ptgs2 
(ATATGTTCTCCTGCCTACTGGAA, GCCCTTCACGTTATTGCAGATG); Primer 1 
(Fig. 2.6D, AGCGAGGACCTGGGTTCAC); Primer 2 (Fig. 2.6D, 
TGGGTGTGATTTGTTTGGCATGG); Primer 3 (Fig. 2.6D, 
GGATACACCTCTCCACCAATGAC); Fgfr1b (GGGAATTAATAGCTCGGATG, 
CCACAGGTCTGGTGACAGTG); Fgfr1c (CCAGATCCTGAAGACTGCTG, 
GAGTCCGATAGAGTTACCCG); Fgfr2b (CTCGGGGATAAATAGCTCCA, 
GGAAGCCGTGATCTCCTTCT); Fgfr2c (GGGAATCGCTAGAGTTGCAG, 
TGTCGTCCTCATCATCTCCA); Fgfr3b (CAAGTTTGGCAGCATCCGGCAGAC, 
TCTCAGCCACGCCTATGAAATTGGTG); Fgfr3c 
(CAAGTTTGGCAGCATCCGGCAGAC, CACCACCAGCCACGCAGAGTGATG); 
Fgfr4 (GCCCTTCACGTTATTGCAGATG, CCTCTCCAACCCCGTACTC); Ptgs1 
(AGTGCGGTCCAACCTTATCC, GCAGAATGCGAGTATAGTAGCTC); CD14 
(CTCTGTCCTTAAAGCGGCTTAC, GTTGCGGAGGTTCAAGATGTT); Tlr4 
(GCCTTTCAGGGAATTAAGCTCC, AGATCAACCGATGGACGTGTAA); Myd88 
(AGGACAAACGCCGGAACTTTT, GCCGATAGTCTGTCTGTTCTAGT); MD-2 
(CGCTGCTTTCTCCCATATTG, GTCTTATGCAGGGTTCAGAAC); IRAK-M 
(CTGGCTGGATGTTCGTCATATT, GGAGAACCTCTAAAAGGTCGC); TNF-α 
(CCCTCACACTCAGATCATCTTCT, GCTACGACGTGGGCTACAG); I-Ab 
(CCCTCATCAGGGAGAGGTCTA, CCGATGCCGCTCAACATCT); CUGbp2 
(GCTGCTTCAACCCCCAATTC, CGCCATACCTGCTAGTGCAT). 
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Immunoblotting- Colonic MSCs were treated as noted. Following treatment, cells were 
lysed in RIPA buffer (Sigma) containing Protease and Phosphatase inhibitor cocktails 
(Sigma) and frozen at -80°C. Protein content was reduced by heating to 95°C for 5min in 
a ratio of 1:1 with 2X Laemmli’s buffer. Protein was loaded onto 10% or 4-12% Bis-Tris 
gels (Invitrogen) and electrophoresed with MOPS buffer (Invitrogen). Samples were 
transferred to a 0.45µm nitrocellulose membrane (BD) and blocked in 5% milk in 0.05% 
Tween 20 TBS (TBST) overnight at 4°C. Blots were incubated for 2hrs at room 
temperature in primary antibody, washed three times in TBST, incubated for 1hr in HRP 
conjugated anti-rabbit secondary (1:10,000, Bio-Rad) before development using 
SuperSignal West Dura chemiluminescent kit (Pierce). Primary antibodies were specific 
for phospho-Erk (diluted 1:500; Cell Signaling Technologies), CUGbp2, and actin (each 
diluted 1:500; Sigma). Quantitation was performed using ImageJ software. 
FACS analysis- For analysis of extracellular molecules, cultured cells were treated with 
trypsin/EDTA, pelleted, and resuspended in 100µl FACS buffer (1% BSA in PBS) with 
the appropriate primary antibody for one hour, washed three times in FACS buffer, 
incubated in 100µl FACS buffer with the appropriate secondary antibody, washed again, 
and analyzed on a FACSCalibur flow cytometer. Analysis was performed using FlowJo 
software. For analysis of intracellular enzymes, cells were fixed after suspension in 50% 
methanol in PBS for 10min at -20°C followed by 90% methanol overnight at -20°C. Cells 
were then stained and analyzed by the same methodology for extracellular molecules. 
Antibodies employed at 1:100 dilution were CD3ε (BD Pharmingen), CD11b (BD 
Pharmingen), CD11c (BD Pharmingen), CD29 (BD Pharmingen), CD31 (BD 
Pharmingen), CD34 (eBioscience), CD44 (BD Pharmingen), CD45 (BD Pharmingen), 
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CD54 (eBioscience), CD90 (Caltag Laboratories), CD105 (eBioscience), CD106 
(eBioscience), Sca-1 (BioLegend), B220 (BD Pharmingen), F4/80 (Caltag Laboratories), 
NK1.1 (BD Pharmingen), Gr-1 (BD Pharmingen), I-Ab (BioLegend), and Ptgs2/Cox-2 
(BD Pharmingen). 
Global Gene Array analysis- RNA from two cultured cell lines each of cMSCs and 
bmMSCs was isolated using QiaShredders and Qiagen RNEasy mini kit according to 
instructions. RNA was measured on a nanodrop machine and amplified in one-step using 
RiboAmp Plus from MDS Analytical Technologies according to provided protocol. 
Amplified RNA was labeled with Turbo Labeling Biotin (MDS) and fragmented before 
hybridization onto MOE430A microarray chips from Affymetrix. Analysis of data was 
performed using dCHIP software115 and gene ontology comparisons116. Significance of 
differential expression was set at 1.3 fold difference with p<0.05. 
Immunohistochemistry- Mice were sacrificed and colons removed, flushed with room 
temperature PBS, opened, and pinned in 2% paraformaldehyde for 30 minutes. Tissue 
was then rinsed in 5% sucrose PBS and blocked in OCT. Seven micron sections were cut 
and stained by blocking in 2% dry milk PBS, incubating for 1 hour in primary antibody, 
washing, incubating for 45 minutes in secondary antibody, staining with Hoechst nuclear 
dye, and finally coverslipping with 1:1 glycerol:PBS solution. Sections were viewed with 
a Zeiss Axiovert 200 with Axiocam MRM camera. Antibodies used in staining are found 
in the FACS analysis section. 
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Chapter 2: Results 
Ptgs2-expressing stromal cells co-localized with markers of mesenchymal stem cells 
(MSCs). Previously we found that stromal cells in the colonic mesenchyme expressed 
high levels of Ptgs2 in stained tissue sections co-labeled with CD44 but not with 
definitive hematopoietic, myofibroblast, or endothelial cell markers14. We noted that 
other investigators found that CD44 was common in all mesenchymal stem cells (MSCs) 
isolated from a wide array of mouse tissues39. Therefore, we tested the hypothesis that 
Ptgs2-expressing stromal cells were tissue resident MSCs by screening a variety of MSC 
markers. CD29 (integrin β1) and CD44 (hyaluronate binding protein) were selected as the 
best current defining markers for MSCs of all tissues39 while CD54 (Icam1), CD105 
(endoglin), and CD106 (Vcam1) are commonly described in numerous MSC lines (e.g. 
45). We confirmed our previous work that demonstrated Ptgs2-expressing cells co-
expressed CD4414 (Fig. 2.1A). Using double label immunofluorescence on colonic 
sections from WT mice, we also found Ptgs2-expressing cells co-stained with the 
remaining MSC markers (Fig. 2.1B-E), supporting our hypothesis. We also confirmed 
our previous analysis that the Ptgs2-expressing stromal cells lacked expression for all 
hematopoietic markers tested including F4/80 (macrophages, Fig 2.1F), CD68 
(macrophages), CD3ε (T cells), CD45, B220 (B cells), Gr-1 (granulocytes), and NK1.1 
(NK cells) as well as markers of endothelial cells (CD31/Pecam) and prolyl-4-
hydroxylase and fibroblast specific protein14. Taken together, these data generate a 
hypothesis that the Ptgs2-expressing stromal cells are MSCs. 
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Figure 2.1 
 
Figure 2.1. Ptgs2-expressing stromal cells co-localize with markers of mesenchymal 
stem cells in vivo.  
Sections of the rectum from WT C57Bl/6 mice co-stained with Alexa fluor 594 
Zenon labeled-anti-mouse Ptgs2 IgG1 (red) and various MSC and hematopoietic 
markers. All MSC markers (A-E) were visualized with an Alexa Fluor 488-
conjugated anti-rat Ig secondary used to detect  (A) rat anti-mouse CD44, (B) rat 
anti-mouse CD29, (C) rat anti-mouse CD54, (D) rat anti-mouse CD105, and (E) rat 
anti-mouse CD106. The hematopoietic co-staining marker was (F) FITC-conjugated 
F4/80. Yellow dashed lines denote the basolateral membrane of the epithelium. (G) 
Magnified insets of the dashed boxed portions of A-F. Ptgs2 co-labels with all MSC 
markers but not F4/80. Bars = (A-F) 20 µm (G) 15 µm. 
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Isolated colonic stromal cells were identified as MSCs and exhibited marker 
expression similar to Ptgs2 expressing stromal cells in vivo. MSCs are multi-potent 
progenitors for a number of mesenchymal cell types that have been isolated from many 
mouse and human tissues39,41. One of their functions is to mediate tissue repair either 
through the secretion of various factors or by differentiation into specific cell types (e.g. 
117). To test our hypothesis that Ptgs2-expressing stromal cells are MSCs, we isolated 
MSCs from the adult mouse colon by the technique originally developed by Freidenstein 
and colleagues40 and modified for a wide array of mouse organs39. Briefly, collagenase-
dissociated colonic cells were plated for one hour, and the adherent cells were expanded 
and analyzed. We have maintained cell lines produced in this manner for at least 40 
passages in culture as has been described for MSCs isolated from other organs.  
We characterized the putative MSC cell lines isolated from the mouse colon in order 
to determine whether these cells were representative of the Ptgs2-expressing cells that we 
identified in vivo.  Cells cultured in low-glucose DMEM with 10% serum were used to 
analyze expression of pertinent surface proteins identified in vivo.  Single channel flow 
cytometric analysis of the colonic stromal cells showed expression of CD29, CD44, 
CD54 and CD106 in all lines isolated from WT colons (n=5) at early passages (P3-5; Fig 
2.2A). Expression of these markers was stably maintained up to P40 (data not shown). 
Interestingly, we could detect expression of CD105 in cells after initial isolation and 
expansion, but expression of this marker was undetectable by P3 (Fig 2.2A). These 
putative MSCs also lacked expression of hematopoietic markers (CD11b, CD11c, B220, 
CD3ε, F4/80, CD45, NK1.1, Gr-1, I-Ab) and endothelial markers (CD31/Pecam).  Most 
significantly, these cells co-expressed Ptgs2 with CD44 and CD106 as demonstrated by 
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dual label flow cytometry (Fig. 2.2B). Taken together, these data suggested that the 
isolated and expanded stromal cells were representative of the stromal cells identified by 
strong Ptgs2 immunofluorescence in vivo14. 
We then performed expression analysis of CD90, Sca-1 and CD34. These proteins are 
additional markers of various, organ-specific MSCs (isolated from spleen, muscle, blood 
vessels, kidney, lung, liver, brain, and thymus) that are known to show variation in 
expression39. The isolated colonic stromal cells expressed all three of these markers (Fig. 
2.2A). This finding recapitulated analysis of marker proteins from bone marrow (bm) 
MSCs with the exception of  CD34, which is commonly reported to be absent on 
bmMSCs44,118.  
We then determined if the isolated colonic stromal cell lines had properties of bona 
fide MSCs. Like all other MSCs, the colonic stromal cells were able to differentiate into 
osteocytes and adipocytes when cultured under appropriate conditions as demonstrated 
by staining by Alizarin Red S and Oil Red O respectively41,42 (Fig. 2.2C).  This capacity 
confirmed the multipotency of these cells.  Furthermore, the isolated cells were capable 
of modulating immune function as has been previously shown for bmMSCs45,53. Co-
culture of the colonic stromal cells with anti-CD3/CD28-activated splenocytes resulted in 
significantly decreased splenocyte proliferation (to a ratio of splenocytes:cMSCs of 20:1) 
in a dose-dependent manner as measured by incorporation of H3 thymidine (Fig 2.2D).  
As in similar experiments with bmMSCs,45 culture media from the colonic stromal cells 
also significantly decreased splenocyte proliferation (Fig. 2.2D).  Taken together, these 
data confirm that our isolated colonic stromal lines have the properties of MSCs and were 
therefore termed cMSCs. 
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Figure 2.2 
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Figure 2.2. Isolated colonic stromal cells are mesenchymal stem cells and maintain 
Ptgs2 expression 
(A) Representative histograms of flow cytometric analysis of cultured colonic 
stromal cells (n=5 lines) at passage 3-5 stained for the markers shown (blue lines). 
Antibodies to CD11b, CD11c, CD90, Sca-1, B220, CD3ε, F4/80, CD45, NK1.1, 
Gr-1, and I-Ab were pre-conjugated FITC- or Alexa-fluor 488-labeled primary 
mouse antibodies. Cells labeled with CD29, CD34, CD44, CD54, CD105, CD106, 
and CD31 were detected with an Alexa-fluor 488 conjugated anti-rat secondary. 
Controls were antibodies of the same isotype (red lines). (B) Representative double 
label flow cytometric analysis of colonic stromal cells (n=3 lines) co-stained with 
either CD44 or CD106 as described above and Ptgs2 detected by Alexa-fluor 647 
conjugated anti-mouse antibody. (C) Representative histological images of colonic 
stromal cells (n=3 lines) which were plated on coverslips and treated for 21 days in 
appropriate media conditions (see Materials and Methods). Following incubation, 
cells were fixed and stained for calcium deposition by Alizarin Red S or for lipid 
deposition by Oil Red O. Undifferentiated cells plated two days before staining 
were likewise visualized. Bar=50µm. (D) Graph of H3 thymidine incorporation by 
splenocytes (spl). Splenocytes were plated with or without activation by antibodies 
to CD3ε and CD28 in triplicate in 96 well plates. Colonic stromal cells were 
similarly plated either alone or at varying ratios with splenocytes. Error bars 
represent standard deviation. Statistical analysis by ANOVA and Bonferroni post-
test *(p<0.05), **(p<0.01), ***(p<0.001), n.s.(not significant). 
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High constitutive Ptgs2 expression was unique to cMSCs. Based on previous 
experiments in colonic injury repair13,16,109,110, our hypothesis was that one key defining 
characteristic of cMSCs is their expression of high levels of Ptgs2 and consequent 
production of high levels of PGE2. We first directly compared the expression of Ptgs2 in 
and secretion of PGE2 from cMSCs isolated from WT versus Ptgs2-/- mice. This analysis 
showed that Ptgs2 activity accounted for > 99.9% of secreted PGE2 (Fig. 2.3A, B). We 
also compared our cMSC lines to other major colonic cell types capable of expressing 
high Ptgs2 in certain circumstances: macrophages119 and epithelial tumor cells120. We 
found that cMSCs contained 74-fold higher levels of Ptgs2 mRNA when compared to 
bone marrow-derived macrophages and >1000-fold higher levels of secreted PGE2. In 
comparison of gene expression in cMSCs and a model tumor line (Caco-2 cells), we saw 
that the cMSCs contained 4-fold higher levels of Ptgs2 and produced >4000-fold higher 
levels of PGE2.  
We then assessed whether the high levels of Ptgs2 in cMSCs were a general property 
of MSCs, as bmMSCs have also been reported to produce PGE245. Therefore we isolated 
MSCs from a variety of adult mouse organs including the bone marrow, lung, and 
stomach and maintained these MSCs in culture as we did for cMSCs.  Interestingly, the 
cMSCs contained the highest levels of Ptgs2 mRNA (range of 5-10 fold greater message) 
and produced the highest levels of PGE2 (range of 10-25 fold) in comparison with all of 
these other MSC lines (Fig. 2.3A, B). 
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Figure 2.3 
 
Figure 2.3. High constitutive Ptgs2 expression is unique to cMSCs.  
(A) Graph comparing Ptgs2 expression by quantitative RT-PCR in various cell lines 
(baseline=cMSCs isolated from Ptgs2-/- mice). MSC lines were isolated from the 
colon (n=7 lines), stomach (n=4 lines), bone marrow (n=4 lines), and lung (n=2 
lines) of WT C57Bl/6 mice and colon of Ptgs2-/- mice (n=2 lines). Macrophages 
(n=2 lines) were derived from bone marrow of C57Bl/6 mice with differentiation in 
L-cell supernatant. Caco2 cell data represents n=2 different passages. All cDNAs 
used in qRT-PCR were synthesized using random hexamer primers. Statistical 
markings (asterisks) refer to comparison to WT cMSC Ptgs2 expression. (B) Graph 
of PGE2 secretion measured by ELISA assay of various cell lines described above. 
Statistical markings refer to comparison to WT cMSC PGE2 secretion. Error bars 
represent standard deviation. Statistical analysis by Student’s t test: *(p<0.05), 
**(p<0.01), ***(p<0.001), n.s.(not significant). 
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High constitutive Ptgs2 expression was not due to TLR stimulation. We considered 
two possible explanations for the observed high constitutive expression of Ptgs2 in 
cMSCs: 1) that it is cell autonomous or 2) that it requires endogenous signal(s) from the 
local environment of the colon that educate the cells to express abundant Ptgs2. These 
endogenous signals could be derived from the host and/or from the indigenous microbes.  
Because cMSCs are located in the colon and would thus potentially be exposed to 
microbes and/or microbial products, we first tested the hypothesis that the high levels of 
Ptgs2 expression may be induced/maintained via toll-like receptor (Tlr) signaling. To test 
this idea, we isolated cMSCs from adult C57Bl/6 germ free (GF) mice that lacked all 
microbes. Interestingly, GF cMSCs contained similar levels of Ptgs2 expression as 
conventionally raised (CONV) mice that contained the normal gut microbiota (Fig. 2.4A), 
indicating that in vivo TLR stimulation was not necessary during cMSC development to 
produce high levels of Ptgs2.   
The striking result obtained using GF cMSCs led us to determine if cMSCs could 
respond to TLR stimulation. In the normal colon, one dominant TLR ligand is 
lipopolysaccharide (LPS). Therefore, we tested the response of cMSCs isolated from 
CONV mice to LPS stimulation. We considered the possibility that a lack of response in 
the CONV mice could be the result of attenuation of TLR signaling due to microbial 
stimulation of these cells while in the mouse gut121,  so we also evaluated the response of 
GF cMSCs to account for this possibility.  We found that stimulation of either CONV or 
GF cMSCs with LPS (at concentration ranges from 1 – 100 ng/ml) showed no significant 
induction of Ptgs2 as compared to untreated CONV and GF cMSCs, respectively. As a 
positive control, we similarly treated bone marrow-derived macrophages (a cell type 
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known to respond to LPS) isolated from adult C57Bl/6 mice and found that these cells 
demonstrated >150 fold increase in Ptgs2 expression upon incubation with LPS (Fig. 
2.4B) that corresponded with an increase of >200 fold in prostaglandin E2 (PGE2) 
secretion (Fig. 2.4C).These results suggested that the high constitutive level of Ptgs2 
expression in cMSCs was not the result of an in vivo microbe-dependent maturation.  
We next identified a potential mechanism for the lack of cMSC response to LPS by 
comparing expression of various members of the Tlr4 pathway in cMSCs versus bone 
marrow-derived macrophages.  By qRT-PCR analysis, expression levels of many genes 
important in relaying the LPS signal were statistically significantly lower in untreated 
cMSCs than untreated macrophages, including Tlr4 (fold difference = -30) and CD14 
(fold difference = -50; Fig. 2.4D).  The near lack of CD14 expression in cMSCs is likely 
important as this molecule is a necessary component for recognition of LPS by Tlr4122.  
Lastly, macrophages predictably responded to LPS stimulation by alteration of the 
expression of TLR-pathway members including IRAK-M, MHC Class II (I-Ab), and Ptgs2 
(Fig. 2.4E). Analysis of similarly treated cMSCs did not show significant changes in the 
expression of any of these genes (Fig. 2.4E). This expression analysis confirms that the 
high constitutive expression of Ptgs2 in cMSCs was likely not the result of TLR-
stimulated maturation. 
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Figure 2.4 
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Figure 2.4. High constitutive expression of Ptgs2 is not due to TLR activation. 
Colonic MSCs from CONV and GF mice and bone marrow-derived macrophages 
were isolated and analyzed. (A) Graph of Ptgs2 expression difference in cMSCs 
isolated from CONV (n=3 lines) and GF mice (n=2 lines) measured by qRT-PCR 
(baseline: cMSCs from CONV Ptgs2-/- mice). p=0.220, Student’s t test. (B) Graph 
of Ptgs2 expression difference in MSCs and macrophages plated and stimulated by 
LPS (1-100ng/ml) for 21 hours (baseline: unstimulated cells). (C) Graph of PGE2 
secretion fold difference (baseline: secretion from unstimulated cells) from cells 
stimulated by LPS measured by ELISA assay of supernatants from cMSC (n=3 
lines) and macrophages (n=3) (baseline=secretion from unstimulated cells). (D) 
Graph of TLR4 pathway member gene expression fold difference in cMSCs (n=3 
lines) baselined to macrophages (n=3 lines) for each gene measured by qRT-PCR. 
(E) Graph of fold expression difference in members of the TLR4 pathway and 
target genes measured by qRT-PCR in 21-hour LPS-stimulated cells (baseline: 
unstimulated cells). Statistical markings represent significance in the fold difference 
of a given gene in cMSCs compared to the fold difference of that gene in 
macrophages. Error bars represent standard deviation. Statistical analysis by 
ANOVA and Bonferroni post-test (B) or Student’s t test (A, E): *(p<0.05), 
**(p<0.01), ***(p<0.001). 
 
Comparison of global gene expression between organ-specific MSCs revealed 
candidate pathways that could enrich for Ptgs2 expression in cMSCs. As microbially-
derived signals did not appear to participate in the high endogenous levels of Ptgs2 
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expression in cMSCs, we evaluated signals from other host cells. A proven method for 
identifying upstream candidates in a target cell type is global gene expression analysis. 
To identify cMSC-specific Ptgs2 regulatory pathways, we compared these cells to 
bmMSCs because: 1) they expressed less Ptgs2/PGE2 than cMSCs and 2) they shared 
important properties with cMSCs (i.e. multipotency and immune modulation). 
We probed Affymetrix MOE430A microarrays with cRNA amplified from total RNA 
procured from two independently isolated lines of cMSCs and bmMSCs. We analyzed 
the data using dCHIP software115 and generated a list of 575 probe sets (corresponding to 
427 unique genes) that were elevated in the cMSCs as compared to bmMSCs (using a 1.3 
expression fold difference cut-off and p<0.0513; this data is deposited on the GEO 
database: http://www.ncbi.nlm.nih.gov/geo/). Importantly, this list included Ptgs2 (11-
fold difference) and CD34 (200-fold difference) which correlated with the observed 
differences in protein expression between these two cell lines (data not shown).  
We then functionally categorized the genes that were enriched in cMSCs and 
bmMSCs using gene ontology (GO) terms116. The three most highly represented 
categories of genes preferentially expressed in cMSCs were ‘integral to membrane’ 
(fractional representation: 0.284), ‘protein binding’ (fractional representation: 0.275), and 
‘membrane’ (fractional representation: 0.275). Conversely, the three most highly 
represented GO terms in bmMSCs were ‘protein binding’ (fractional representation: 
0.354), ‘membrane’ (fractional representation: 0.320), and ‘nucleus’ (fractional 
representation: 0.296).  The most striking feature of this analysis was that the ‘integral to 
membrane’ GO term was the most highly represented in the cMSC list. This is quite 
unusual for a stem cell123, and we therefore focused closely on this subset of genes.  
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In order to narrow the list of candidates involved in the regulation of high levels of 
Ptgs2 in cMSCs from the 94 genes in the ‘integral to membrane’ category, we reasoned 
that genes of interest would also be capable of receiving and transducing an extracellular 
signal. Therefore, we required that genes of interest also contain the GO terms ‘integral to 
plasma membrane’ (genes = 25) and ‘receptor activity’ (genes = 35). The intersection of 
‘integral to membrane’ genes that contained these two additional GO terms generated a 
list of 13 genes (Fig. 2.5A) that were enriched in cMSCs as compared to bmMSCs (Fig. 
2.5B). Interestingly, these 13 genes could be loosely categorized into the receipt of three 
general types of signals: growth, immune, and neural (Fig. 2.5B).  
We further evaluated the possible role of Fgfr1 because previous studies in our 
laboratory demonstrated that communication between Fgf9 and MSCs in the intestinal 
tract exists during development124, thus demonstrating the ability of at least one type of 
MSC to respond physiologically to Fgf signaling. PCR analysis of cDNA isolated from 
whole WT adult colon showed that all four Fgf receptors were expressed, including all ‘b’ 
and ‘c’ splice forms. The ‘b’ forms are expressed predominately in epithelial cells, and 
the ‘c’ forms are expressed predominately in mesenchymal cells125,126 (Fig. 2.5C). We 
then performed qRT-PCR for Fgfr1, 2, 3, and 4 using total RNA isolated from cMSCs 
and found that cMSCs contained detectable expression of only the ‘c’ form of Fgfr1 and 
Fgfr2 (Fig. 2.5D). This expression analysis confirmed that signaling by Fgf ligands to 
cMSCs was possible. We then focused on the role of Fgf9 as it is expressed in the 
epithelium of the colon127 and appears to signal to MSCs during development124.  
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Figure 2.5 
 
Figure 2.5. Comparison of cMSCs to bmMSCs reveals possible mechanistic 
pathways involved in Ptgs2 expression. 
(A) Venn diagram illustrating the intersection of the gene ontology (GO) terms 
‘integral to plasma membrane’ and ‘receptor activity’ obtained through GO analysis 
of genes preferentially expressed in cMSCs (compared to bmMSCs). Data for 
analysis was obtained by isolation of total RNA from cMSCs (n=2 lines) and 
bmMSCs (n=2 lines), amplification and cRNA labeling, hybridization to 
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Affymetrix MOE430A microarrays, and dCHIP analysis of genes preferentially 
expressed in one cell type or the other at a 1.3 fold level, p<0.05. (B) Heat map 
generated by dCHIP software of genes fitting into the logical intersection of 
‘integral to plasma membrane’ and ‘receptor activity’ showing relative expression 
levels in each cell line. (C) Electrophoresis gel of PCR reaction amplifying cDNA 
obtained from whole WT C57Bl/6 mouse intestine for the Fgf receptor splice 
forms: Fgfr1b, Fgfr1c, Fgfr2b, Fgfr2c, and Fgfr4 (annealing temperature = 60°C) 
and Fgfr3b and Fgfr3c (annealing temperature = 65°C). (D) Graph of qRT-PCR 
measurements of the various splice forms of the Fgf receptors expressed in cMSCs 
(n=3 lines) compared to water control. Error bars represent standard deviation. 
 
Fgf9 was sufficient to maintain high levels of Ptgs2 expression in cMSCs. We 
hypothesized that Fgf9 stimulation may be responsible for induction and/or maintenance 
of Ptgs2 expression in cMSCs.  Therefore, we studied its effects on expression in cMSCs 
in vitro.  Colonic MSCs were serum starved to remove the growth factor signaling that 
was present during standard tissue culture.  As little as 3 hours of starvation resulted in an 
approximately 25-fold decrease of Ptgs2 expression while expression of other genes, 
notably Ptgs1, was unaffected within this time frame (Fig. 2.6A).  This loss of Ptgs2 
mRNA was rescued in a dose dependent manner by the addition of Fgf9 (range of 1 – 
500ng/ml) to the culture media for one hour (Fig. 2.6B).  This treatment had no effect on 
expression of Ptgs1.  Addition of Fgf9 was sufficient to rescue Ptgs2 expression to a 
similar level as the addition of 10% serum.  The effects of exogenous Fgf9 on Ptgs2 
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mRNA levels could be blocked by addition of a neutralizing antibody directed against 
Fgf9 (Fig. 2.6C).  
In order to determine whether Ptgs2 mRNA was increased due to transcriptional 
activation or post-transcriptional regulation/stabilization, we designed a transcript-
specific qRT-PCR assay.  Primers were designed to amplify a product specifically from 
the unspliced (unprocessed) form of Ptgs2 RNA (primers 1 and 2) or to amplify a product 
specifically from the spliced (mature) form of Ptgs2 RNA (primers 1 and 3; Fig. 2.6D).  
Both the unspliced and spliced forms of Ptgs2 RNA expressed by cMSCs showed 
decreased levels after serum starvation for 3 hours but the effect on spliced mRNA was 
much more pronounced.  Treatment with 100ng/ml of Fgf9 after starvation significantly 
rescued both the spliced and unspliced forms of Ptgs2 RNA (Fig. 2.6E). These data 
suggest that Fgf9 may regulate Ptgs2 RNA expression at either the transcriptional or 
post-transcriptional level.  
In order to better delineate between the two levels of regulation, we devised an 
experiment to specifically test the effect of Fgf9 on the post-transcriptional regulation of 
Ptgs2. To do this, we removed the possibility of Fgf9 affecting Ptgs2 expression at the 
transcriptional level by blocking transcription in cMSCs with actinomycin D treatment 
(4μg/ml). Blockade of transcription in cMSCs cultured with 10% serum in the media had 
no significant effect on the mature Ptgs2 mRNA levels in 3 hours (Fig. 2.6F). This 
finding suggested that a growth factor present in the serum was able to maintain the 
mature form of Ptgs2 mRNA synthesized before transcriptional blockade. As in serum 
starved conditions alone, a significant decrease in Ptgs2 mature mRNA was seen when 
serum starvation was compounded by transcriptional repression by actinomycin D (Fig. 
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2.6F). We suspected that Fgf9 would be sufficient to mediate the stabilization of mature 
Ptgs2 mRNA seen in transcriptional blockade in the presence of 10% serum and tested 
this hypothesis. We found that serum starved cMSCs treated with actinomycin D in the 
presence of Fgf9 (250ng/ml) showed no loss of mature Ptgs2 mRNA, indicating that Fgf9 
is capable of maintaining Ptgs2 expression independent of transcriptional activation (Fig. 
2.6F). Also, as expression of unspliced Ptgs2 should depend completely upon 
transcription, we showed that Fgf9 was unable to rescue the total loss of unspliced Ptgs2 
expression upon blockade of transcription by actinomycin D treatment (Fig. 2.6G).  
These series of experiments confirmed that the serum starvation-induced decrease of 
mature Ptgs2 mRNA expression could be rescued by Fgf9 independent of transcription.  
Thus, Fgf9 was sufficient to maintain mature Ptgs2 mRNA expression and affected this 
expression at a post-transcriptional level. 
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Figure 2.6 
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Figure 2.6. Fgf9 is sufficient to stabilize Ptgs2 mRNA. 
(A-D, G-I) qRT-PCR and (E) immunoblot analysis of cMSCs.  (A) Graph of the fold 
difference for Ptgs2 and Ptgs1 expression of serum starved cMSCs versus cMSCs 
grown in 10% serum. (B) Graph of the fold difference for Ptgs2 and Ptgs1 expression 
in cMSCs after 1hr Fgf9 treatment (range=1 – 500ng/ml) following 3hr serum 
starvation. (C) Graph of the fold difference for Ptgs2 expression after treatment with 
Fgf9 or Fgf9 plus anti-Fgf9 neutralizing antibody following 3hr serum starvation. (D) 
Schematic illustrating the location of primers 1, 2 and 3 on the Ptgs2 gene. (E) Graph of 
the fold difference for the spliced and unspliced forms of Ptgs2 isolated from 3hr serum 
starved cMSCs additionally treated for 1hr with Fgf9. (F) Graph showing the fold 
difference for Ptgs2 spliced RNA after treatment with or without serum starvation, 
4µg/ml actinomycin D, and 250ng/ml Fgf9. Asterisks compare data to fold difference 
in cells treated with 0% serum and actinomycin D. (G) Graph showing the fold 
difference for Ptgs2 unspliced RNA with or without serum starvation, 4µg/ml 
actinomycin D, and 250ng/ml Fgf9 (UD = undetectable). All data is representative of 
three independent experiments. Error bars represent standard deviation. Statistical 
analysis by Student’s t test: *(p<0.05), **(p<0.01), ***(p<0.001), n.s.(not significant). 
 
Fgf9 stabilizes Ptgs2 mRNA in part through CUGbp2. To investigate the mechanism 
of Fgf9-mediated Ptgs2 mRNA stabilization, we first tested the role of Erk, a component 
of the MAP kinase cascade capable of transducing Fgf signaling in many cells128.  Erk 
activation was inhibited by use of the MEK inhibitor PD98059.  We found that an 
increasing dosage of PD98059 in cMSCs decreased phosphorylation of Erk and that this 
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treatment also corresponded to a decrease in Ptgs2 mRNA expression (Fig. 2.7A,B).  As 
expected Erk phosphorylation is also decreased in the absence of serum.  These results 
support the role for Erk activation in Ptgs2 stabilization. 
We then undertook a candidate molecule approach to identify possible proteins which 
could be downstream targets of Fgf9/Erk activation. Our microarray data (Fig. 2.5) 
identified multiple mRNA binding proteins that were preferentially expressed in cMSCs 
compared to bmMSCs. One of these was CUGbp2, a protein known to stabilize Ptgs2 
mRNA36,38 and whose activity can be regulated by phosphorylation downstream of 
growth factors30.  We evaluated this gene at both the mRNA and protein level in the 
context of Erk inhibition and found that although CUGbp2 mRNA was not significantly 
altered by either serum starvation or by Erk inhibition (Fig. 2.7A), the level of 
endogenous CUGbp2 protein was decreased both in the absence of serum and upon Erk 
inhibition (Fig. 2.7B, C). 
This result suggested that CUGbp2 protein was required to stabilize Ptgs2 mRNA in 
cMSCs. We tested this idea by specifically inhibiting CUGbp2 protein translation 
through shRNA-mediated knockdown of CUGbp2 expression.  Lentiviral transfection of 
cMSCs with two different CUGbp2-specific produced significant knockdown of 
CUGbp2 mRNA as measured by qRT-PCR (Fig. 2.7D). Importantly, transfection with 
control shRNA did not affect CUGbp2 expression. The shRNA-mediated decrease of 
CUGbp2 mRNA corresponded to a decrease in CUGbp2 protein expression as 
demonstrated by immunoblot (Fig. 2.7E). We then assessed the effect of CUGbp2 loss on 
Ptgs2 expression and observed that in cMSCs. We found a significant decrease in Ptgs2 
message level in agreement with other studies in other cell lines30,36 (Fig. 2.7F). 
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Based on these results, we hypothesized that Fgf9 may act through Erk to increase 
CUGbp2 protein. To test this hypothesis, we repeated our previous experiments and 
assessed phosphorylation of Erk and quantity of CUGbp2 protein in cells treated in 
normal serum, in 0% serum, and in 0% serum supplemented only with Fgf9 protein.  We 
observed an increase in both Erk phosphorylation in Fgf9-treated cells as well as 
increased levels of endogenous CUGbp2 protein (Fig. 2.7G, H).  Taken together, these 
observations suggest that the mechanism of Ptgs2 mRNA stabilization by Fgf9 signaling 
is partially mediated through phosphorylation of Erk, leading to increased CUGbp2 
protein, resulting in CUGbp2-mediated stabilization of Ptgs2 mRNA (Fig. 2.8). 
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Figure 2.7 
 
Figure 2.7. Fgf9 stabilizes Ptgs2 partially through Erk activation and increased 
CUGbp2 protein. 
(A) Graph of the fold difference for Ptgs2 and CUGbp2 mRNA following a 3h 
treatment of cMSCs with an Erk kinase inhibitor, PD98059 (100µM or 300µM), or 
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0% serum. (B) Reducing immunoblot of PD98059-treated cMSCs probed for actin 
(loading control), phosphorylated-Erk, and CUGbp2. (C) Graph of the 
quantification of (B) showing the ratio of CUGbp2/actin protein quantity in cMSCs 
treated by serum starvation or with PD98059. Baseline (1.00) = ratio of cMSCs 
grown in 10% serum. (D) Graph of the fold difference in CUGbp2 mRNA in 
cMSCs lentivirally transfected with control shRNA or CUGbp2 shRNAs compared 
to vector control. (E) Reducing immunoblot of cMSCs transfected with vector 
control, control shRNA, or CUGbp2 shRNA showing specific knockdown of 
CUGbp2 protein. (F) Graph of the fold difference for Ptgs2 mRNA in cMSCs 
transfected with control shRNA and CUGbp2 shRNA versus vector control. (G) 
Reducing immunoblot of cMSCs treated with 10% serum, 0% serum, or 0% serum 
plus Fgf9 (250ng/ml) and quantification (H) of the ratio of CUGbp2/actin in these 
cells. Baseline (1.00) = ratio of cMSCs grown in 10% serum. Immunoblots and 
quantifications were representative of three independent experiments. (A,D,F) 
Asterisks compare data to fold difference in cells grown in 10% serum.  Statistical 
analysis was performed by Student’s t test: *(p<0.05), **(p<0.01). 
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Figure 2.8 
 
Figure 2.8. Model of Fgf9 regulation of Ptgs2 expression in cMSCs.   
Colonic MSCs express CD29, CD34, CD44, CD54, CD90, CD105, CD106, Sca-1, and 
Ptgs2. When Fgf9 is present, it signals through Fgfr1c and/or Fgfr2c on the cell surface. 
Transduction of this signal via Erk phosphorylation and activation results in an increase 
in CUGbp2 protein. This protein in turn binds to Ptgs2 mRNA and stabilizes the 
message. In the absence of Fgf9, Erk phosphorylation is decreased, resulting in 
decreased CUGbp2 protein quantity and loss of Ptgs2 mRNA stabilization. 
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Chapter 2: Discussion 
Here we define a previously unidentified Ptgs2-expressing cell population within the 
adult mammalian intestine as mesenchymal stem cells.  We demonstrated a novel 
mechanism by which the observed constitutive expression of Ptgs2 is maintained within 
these cells downstream of Fgf9, a growth factor expressed in the adult mammalian 
intestine.  Our investigations suggest that the stabilization of Ptgs2 mRNA downstream 
of Fgf9 is mediated via phosphorylation of the MAP kinase signaling cascade member 
Erk followed by increased abundance of CUGbp2 protein (Fig. 2.8). 
Fgfs: role in development and homeostasis. There are at present 22 recognized Fgf 
ligands that can be grouped into seven subfamilies based on phylogenetic analysis. The 
Fgf of interest in these studies, Fgf9, is the namesake for one of these subfamilies that 
also includes Fgf16 and Fgf20. Fgf ligands signal specifically through certain Fgf 
receptors. There are four total receptors with Fgfr1, 2, and 3 expressed as either a ‘b’ or 
‘c’ splice form creating essentially 7 different Fgf receptors129,126. Fgfs are known to play 
important roles in the morphogenesis and expansion of developing structures including 
the lung130,131, limb132, intestine133,124,127, epidermis134, and nervous system135. 
We have demonstrated an interaction between Fgf9 and Ptgs2 in a mesenchymal cell 
type unique to the colon, the colonic mesenchymal stem cell.  Our findings potentially 
expand the growing recognition of the role of Fgfs in homeostasis and normal physiology 
within the adult organism. In particular, Fgfs have recently been shown to aid regulation 
of nutrient and mineral homeostasis. For example, Fgf15 can be induced in the small 
intestinal epithelium and subsequently signal to the liver where it regulates enzymes of 
the bile acid synthesis pathway136. Thus Fgf15 has an important role in enterohepatic 
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homeostatic regulation of bile acid production. In other studies, Fgf23, produced by the 
bone, plays a role in regulating calcium and phosphate homeostasis that requires precise 
control of the kidney, parathyroid, intestine and bone. Fgf23 appears to have multiple 
cellular targets in this regulation137,138. Also, nutrient availability and composition can 
impact expression of specific Fgfs including keratinocyte growth factor139 (KGF also 
known as Fgf7).   Our studies raise the intriguing possibility that another Fgf may be 
acting in a homeostatic role in the adult organism, specifically that Fgf9 may be 
important in maintaining the constitutive expression of Ptgs2 in this specific subset of 
mesenchymal cells which have already been implicated in injury response14. 
Growth factors affecting Ptgs2 expression. Our studies have implicated Fgf9 as a 
factor sufficient to mediate Ptgs2 mRNA stability.  However, a variety of other growth 
factors are also likely to be capable of regulating Ptgs2 expression in this cell type. These 
factors include Fgfs other than Fgf9140, Egf29,141, and Igf142,143.  
These various growth factors may act via a number of signaling networks that have 
been implicated in the regulation of Ptgs2, many of which are involved in the induction 
of gene expression during the inflammatory response rather than in constitutive 
expression26. Our in vitro studies strongly indicate that, rather than acting primarily via 
transcriptional upregulation, Fgf9 acts at the post-transcriptional level and suggest that 
the mechanism of this interaction partially involves CUGbp2 protein expression. This 
protein and others including HuR and Apobec-1 have been implicated in the regulation of 
Ptgs2 expression in various tumor cell lines36,38 and in an in vivo model of irradiation 
injury144. Comparing the ability of Fgf9 to increase CUGbp2 protein with its ability to 
increase Ptgs2 mRNA stabilization suggests that increased CUGbp2 is only a portion of 
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the overall mechanism downstream of Fgf9 involved in Ptgs2 expression. It is very likely 
that this growth factor is also signaling through other kinase cascade pathways including 
MAPK through Jnk and p38, PKC, and PI3K145. Intriguingly, the Src family of kinases 
has recently also been implicated in the stabilization of Ptgs2 mRNA downstream of 
signaling by platelet derived growth factor30.  The targets of kinase activity must also be 
greater than one.  There are a variety of further mRNA binding proteins that are likely 
involved in this cascade, some well-researched such as HuR38 and others unknown. 
The role of CUGbp2 in stabilizing Ptgs2 expression.  Previous studies have shown 
that CUGbp2 is capable of stabilizing Ptgs2 mRNA via a mechanism requiring binding of 
the protein to the AU rich region of the 3’UTR of the Ptgs2 message30,36,38. Our findings 
contribute to this field by recognition of a mechanism of the regulation of Ptgs2 mRNA 
stability by endogenously expressed CUGbp2. We demonstrated that Ptgs2 stabilization 
is in part dependent on the quantity of endogenous CUGbp2 protein and appears to be 
independent of altered transcription of CUGbp2. The question now is the mechanism by 
which endogenous CUGbp2 protein is increased consequent of Erk activation. The fact 
that CUGbp2 protein is increased downstream of Erk activation suggests a mechanism 
involving protein phosphorylation. Erk may directly phosphorylate CUGbp2 itself 
resulting in stabilization. Alternatively, it may act indirectly through other proteins that 
then stabilize CUGbp2, disrupt CUGbp2 degradation, or increase CUGbp2 translation 
from available mRNA.  Further studies are needed to understand the regulation of 
CUGbp2 itself.   
Constitutive expression of Ptgs2. The presence of constitutive Ptgs2 expression in the 
adult mammal has been well demonstrated14,28,146,147. However, Ptgs2 remains primarily 
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recognized as the inducible cyclooxygenase largely due to its upregulation in 
inflammation and in various cancers148.  However, Ptgs2 knockout mice, though largely 
healthy, do exhibit multiple problems that arise from loss of constitutive expression 
specifically of Ptgs2 that are not found in Ptgs1 knockout mice.  These include defects in 
kidney development and renal function, in reproduction, and in proper bone 
maintenance18.  These data highlight the necessity of understanding the regulation of 
constitutive Ptgs2 expression in addition to understanding the mechanisms involved in 
the upregulation of Ptgs2 in pathological situations.  Our colonic MSCs can serve as a 
prime vessel for investigating the various mechanisms involved in regulating constitutive 
Ptgs2 expression as they are a primary cell type that naturally maintains extremely high 
levels of Ptgs2 mRNA.  The mechanistic findings can then be evaluated in the whole 
organism in order to better understand the basic biology underlying Ptgs2 expression. 
Colonic MSC: monitors of the homeostatic environment? Our findings raise the 
highly intriguing question of the precise role of colon resident MSCs in homeostasis. We 
have demonstrated a probable role as an immune modulator through the production of 
PGE2. Interestingly, cMSCs do not express MHC class II, even after LPS stimulation, 
indicating that they likely are not acting as non-professional antigen presenting cells. We 
followed this line of inquiry from our analysis of receptors whose expression was 
enriched specifically in cMSCs as compared to bmMSCs. Twelve other receptors were 
uncovered in this analysis, each of which raises possibilities for future experimental 
pathways and inquiries into the role of cMSCs. 
We propose that cMSCs, due to their location in the complex environment of the 
mature colonic mesenchyme made up of a great variety of host cell types, are well-
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positioned to act as monitors of the colonic environment. These cells specifically express 
receptors that are capable of receiving signals from a variety of immune and nervous cells, 
rendering them ideal for integrating signals indicative of the state of the organism as a 
whole and of the level of immune activation locally. The cells would thus be poised to 
combine and interpret neural and immune signals, respond to slight changes in their 
activity, and mediate responses directly or indirectly to these fluctuations before serious 
consequences such as full inflammation result. 
Receptors on the surface of the cMSC capable of receiving neurally-derived signals 
include a cholinergic receptor (Chrnb1), a gamma-aminobutyric acid receptor (Gabbr1), 
and a purinergic receptor (P2rx5). These are intriguing in colonic immune homeostasis as 
there is an emerging literature on the cross-talk between the autonomic enteric nervous 
systems and cellular constituents of the immune system149,150. Other receptors on the 
surface of the cMSC identified by our chip analysis are capable of receiving immune 
signals either directly derived from immune effector cells or indirectly as a consequence 
of immune effector cell action. Two of these are activin receptors (Acvrl1 and Acvr2a) 
that recognize this member of the TGF-β superfamily, a factor that may be secreted by 
Th2 cells151 and by dendritic cells152. The expressed adenosine receptor, Adora2b, can 
receive signals important to NK cell activity and regulation153. A receptor capable of 
sensing extracellular nucleotides released in inflammation is also present (P2ry6154). 
Other receptors include interleukin-3 receptor (Il3ra), a vasopressin receptor (Avpr1a), 
and a calcitonin receptor (Ramp3). Indeed, many more receptors capable of sensing other 
neural, immune, and growth factor signals are also likely to be present; we have only 
highlighted those that appear to be enriched in cMSCs compared to bmMSCs. The 
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simultaneous expression of these many and varied receptors on cMSCs and the 
localization of these cells in the complex environment of the colon place them in a prime 
position to act as monitors of the colonic homeostatic environment. This proposed role 
suggests a wealth of future investigative pathways that could aid the gastrointestinal field 
in gaining a greater understanding of the cellular players and mechanisms involved in the 
complex regulation of colonic homeostasis. 
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CHAPTER 3 
 
Imp1 is a novel trans-acting factor involved in Ptgs2 regulation 
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Chapter 3: Abstract 
Prostaglandins have been shown to play important roles in different injury models, 
acting both on proliferation of injured tissue and in modulation of the immune response.  
These lipid mediators are synthesized downstream of the two prostaglandin endoperoxide 
synthetase genes (Ptgs or cyclooxygenase/cox).  Specifically, Ptgs2 has been shown to be 
both inducible in inflammatory cells and constitutively expressed in rare stromal cells of 
various organs.  The expression of this gene is necessary for proper injury response in a 
variety of colonic injury models from chronic inflammation to radiation exposure.  
Herein we show that Ptgs2 is also necessary in the response of the colon to a localized 
biopsy injury.  We demonstrate that insulin growth factor 2 binding protein 1 (Igf2bp1 or 
Imp1) is necessary for full expression of Ptgs2 in cell lines and can interact with Ptgs2 
transcript in the cellular environment.  Furthermore, we show that Imp1 is upregulated 
within the wound bed of colonic biopsy injury and is expressed in the same cell type as 
Ptgs2, suggesting that Imp1 plays an important role in Ptgs2 regulation in response to 
injury. 
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Chapter 3: Introduction 
Injury to the colonic mucosa can occur in a variety of settings including foreign body 
insult and helminth infection.  Mechanical injury during various scope procedures that 
are now common place for screening and intervention of colonic inflammation and 
cancers may occur, though rare155.  Furthermore, acute inflammatory states may also 
develop in infection and diverticulitis156.  The natural sequence of healing and the 
biological signals and cellular interactions required in such injuries are not fully 
understood. 
In order to address this issue, we pioneered a model injury system that induces acute, 
localized trauma, subsequently followed by confined inflammation and healing15.  Mice 
are injured by colonic biopsy, removing a portion of the colonic mucosa.  Injuries then 
heal and can be followed endoscopically over time until sacrifice and histological 
examination.  We have found that healing occurs with a predictable progression over 6 – 
8 days.  Initially we observe increased macrophage and neutrophil infiltration of the 
wound while a single cell epithelial layer, referred to as would associated epithelium 
(WAE), covers the injured area.  Granulation tissue rapidly forms with a high degree of 
vascularization.  Knowledge of the biological signals involved in healing is necessary in 
order to understand the mechanisms directing healing.  Previously, we identified the Th2 
cytokines IL-4 and IL-13 as cytokines that are necessary for proper healing, likely 
through induction of an M2 macrophage phenotype15.  We have become interested in 
other local candidate signaling molecules that may be important in healing. 
We hypothesized that prostaglandin endoperoxide synthetase 2 (Ptgs2, more 
commonly known as cyclooxygenase-2/cox-2) may play a role in healing as it is known 
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to mediate response to other types of injury.  Ptgs2 is one of the two rate limiting 
enzymes responsible for the conversion of arachidonic acid to prostaglandin H2 which is 
the precursor for the various prostaglandins, prostacyclin, and thromboxane that are then 
secreted to mediate various biological functions.  Specifically, prostaglandin E2 has been 
demonstrated to play a role in maintaining proliferation14 and in modulation of the 
immune system in various models of colonic injury including colitis157 and radiation111.  
Additionally, it has been proposed that mesenchymal stem cells which are currently in a 
phase III trial for treatment of Crohn's disease72 may mediate at least some of their anti-
inflammatory effects via secretion of PGE247. Finally, evidence for the importance of 
Ptgs2 in colonic injury comes from various case-control studies and case reports 
demonstrating correlation between non-steroidal anti-inflammatory drugs (NSAIDS), 
which function by inhibiting the Ptgs genes, and induction of colitis or exacerbation of 
established disease158. 
We therefore asked whether Ptgs2 may be similarly required for the proper response 
to a more localized traumatic injury by investigating wound healing in Ptgs2 deficient 
mice.  We found that Ptgs2 is necessary for proper healing response and is expressed in a 
population of stromal cells in the wound bed.  To uncover novel regulators of Ptgs2, we 
employed a candidate approach and demonstrate for the first time that Imp1 protein 
interacts with Ptgs2 mRNA in the cellular environment, is upregulated in colonic biopsy, 
and is co-localized with Ptgs2 in the wound bed. Understanding the various mechanisms 
and pathways involved in the response to biopsy injury could aid medicine in decreasing 
the morbidity of similar conditions and in accelerating treatments.  
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Chapter 3: Materials and Methods 
Immunoprecipitation and RNA isolation.  The open reading frame of Igf2bp1 was cloned 
from cDNA isolated from colonic mesenchymal stem cells with specific primers, 
cccgaattcatgaacaagctttacatcggc (forward) and cccggatcccttcctccgagcctg (reverse), and 
directionally ligated into p3XFLAG-CMV-14 expression vector (Sigma-Aldrich) using 
restriction sites EcoR1 (5’) and BamH1 (3’) in order to create a FLAG-tagged protein 
construct.  Igf2bp1 deletion mutants RRM (primers: Igf2bp1 F and 
cccggatcctgctgccacgggcg) and KH (primers: cccgaattcatgatccctctccggctcc and Igf2bp1 R) 
were similarly cloned and tagged.  NIH3T3 cells were plated in 10cm dishes and 
transfected using FuGene HD reagent (Roche).  After 18-24 hours, dishes were rinsed in 
cold PBS and exposed to 300mJ 254nm UV light on ice.  Cells were scraped, pelleted, 
and lysed by passage through a 26.5 gauge needle using polysome lysis buffer159 (PLB: 
100mM KCl, 5mM MgCl2, 10mM HEPES) supplemented with 0.05% NP-40, 2mM 
vanadyl ribonucleoside complex, 100U RNAse inhibitor, 1:100 phosphatase inhibitor 
cocktails 2 and 3 (Sigma), and 1:40 protease inhibitor cocktail (Sigma).  Cellular debris 
was removed by centrifugation before preclearing the lysate for one hour tumbling at 4°C 
with mouse IgG-conjugated Protein A beads, and samples were saved for total protein 
and RNA fractions.  Lysates were then incubated overnight at 4°C with M2 antibody-
conjugated agarose beads (Sigma).  Beads were washed 3 times with PLB and 3 times 
with PLB-500mM NaCl.  In some cases, bound FLAG-tagged proteins were eluted using 
100µg/ml 3X FLAG peptide (Sigma) for 3 hours.  Beads, total protein, and eluate 
fractions were then either boiled in Laemmli’s buffer for protein isolation or incubated at 
55°C with 30µg Proteinase K and 0.1% SDS in 100µl TBS for 30min, phenol-chloroform 
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extracted, and ethanol precipitated to isolate RNA.  RNA quantity was measured on a 
nanodrop (ND-1000 Spectrophotometer). 
Mice.  All animal experiments were performed in accordance with approved protocols 
from the Washington University School of Medicine Animal Studies Committee. Mice 
involved in this study were housed in microisolator cages, in a specified pathogen-free 
barrier facility following a 12 hour light cycle and fed a standard irradiated chow diet 
(PicoLab Rodent Chow 20, Purina Mills) and water ad libitum. Ptgs2-/- mice19 were 
generated previously on a C57Bl/6 background. C57Bl/6 mice were obtained from the 
National Cancer Institute. 
Colonic biopsy.  We used a high-resolution miniaturized colonoscope system160,161 in 
order to visualize the lumenal side of the colon, create discrete injury of the mucosal 
layer, and monitor regeneration of the mucosa. This system consisted of a miniature rigid 
endoscope (1.9-mm outer diameter), a xenon light source, a triple chip high resolution 
CCD camera, and an operating sheath with 3 French instrument channel and water 
injection bulb used to control inflation of the mouse colon (all from Karl Storz). In order 
to perform the procedure, we monitored the protocol with high resolution (1024 × 768 
pixels) live video and collected images on a color monitor. 
At the beginning of the procedure, mice were anesthetized by ketamine and xylazine. 
The endoscope with outer operating sheath was inserted to the mid-descending colon and 
any feces pellets were removed.  We then inserted 3 French flexible biopsy forceps, and 
removed full thickness areas of the entire mucosa and submucosa. We were careful to 
avoid much removal or full penetration of the muscularis propria. Each mouse was 
biopsy injured at 3–5 sites along the dorsal side of the colon. 
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Immunofluorescence.  Wounded C57Bl/6 or Ptgs2-/- mice were sacrificed and perfused 
with 4% PFA.  After dissection, the colon was flushed with PBS, inflated/flushed with 
4% PFA for 10 seconds, opened longitudinally, and pinned flat in PFA overnight.  
Colons were changed with 20% sucrose-PBS before wounds were dissected and frozen in 
OCT compound.  Samples were cut into 5µm sections and stored at -80ºC.  For staining, 
slides underwent antigen retrieval in citrate buffer for 10min, rinsed in PBS, blocked with 
3% BSA, and incubated with primary antibody for one hour.  Slides were then rinsed, 
incubated with secondary antibody followed by Hoechst dye and mounting with 1:1 
PBS:glycerin.  Sections were viewed with a Zeiss Axiovert 200 with Axiocam MRM 
camera.  Antibodies used were rabbit anti-Ptgs2, goat anti-Imp1 (Santa Cruz), rat anti-
CD31, rat anti-CD45, rat anti-CD44, rat anti-CD29, and rat anti-β-catenin. 
Cell isolation and culture.  Performed as in Chapter 2.  NIH3T3 cells were similarly 
cultured. 
shRNA Transfection.  HEK293T cells were transfected with Mission shRNA constructs 
specific for Igf2bp1 and non-targeting control (Igf2bp1 clones NM_009951.2-1611s1c1, 
NM_009951.2-1874s1c1; Sigma) and lentiviral packaging plasmids using FuGene HD 
reagent (Roche). Following one day transfection, cell media was refreshed and allowed to 
accumulate virus 24 hours. Viral-containing supernatant was used undiluted directly on 
plated cMSCs for 24 hours before adding puromycin (Sigma)-containing media for 
selection of positively infected cells. 
qRT-PCR.  Cells were treated as noted in various experiments before RNA isolation. 
RNA was isolated and purified using a Nucleospin kit (Clontech) according to 
 68
manufacturer’s protocol or as noted for IP experiments. cDNAs were synthesized using a 
Superscript III reverse transcriptase (Invitrogen), primed using random primers. 
Quantitative RT-PCRs were performed in triplicate for each sample using SYBR-green 
master mix (Clontech) and analyzed by an Eppendorf realplex Mastercycler.  The 
following primers were used: 18S (AACCCGTTGAACCCCATT, 
CCATCCAATCGGTAGTAGCG); Ptgs2 (TGCCTGGTCTGATGATGTATG, 
GCCCTTCACGTTATTGCAGATG); Igf2bp1 (CGGCAACCTCAACGAGAGT, 
GTAGCCGGATTTGACCAAGAA); CUGbp2 (GCTGCTTCAACCCCCAATTC, 
CGCCATACCTGCTAGTGCAT). 
Immunoblotting.  Colonic MSCs were treated as noted. Following treatment, cells were 
lysed in RIPA buffer (Sigma) containing Protease and Phosphatase inhibitor cocktails 
(Sigma) and frozen at -80°C. Protein content was reduced by heating to 100°C for 5min 
in a ratio of 1:1 with 2X Laemmli’s buffer. Protein was loaded onto 10% or 12% Tris-
Gly gels (BioRad) and electrophoresed with Tris-Glycine-SDS buffer (BioRad). Samples 
were transferred to a 0.45µm nitrocellulose membrane (BD) and blocked in 5% milk in 
0.05% Tween 20 TBS (TBST) overnight at 4°C. Blots were incubated one hour with 
HRP-conjugated M2 antibody (anti-FLAG, Sigma) before development using 
SuperSignal West Dura chemiluminescent kit (Pierce). 
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Chapter 3: Results 
Ptgs2-/- mice show impaired healing of colonic biopsies. 
In order to determine whether Ptgs2 is required for the proper healing of localized 
injury generated by colonic biopsy, we injured Ptgs2-/- mice and allowed them to heal.  
Histologically, by day 6, wild-type (WT) mice exhibit a contained area of granulation 
tissue bordered by the WAE cells covering the wound bed and by intact muscularis 
propria.  These discrete cellular tissues can be visualized by smooth muscle actin, 
marking the muscularis propria, as well as by CD31, marking endothelial cells (Fig 3.1A).  
CD31 staining demonstrates the vascularization of the granulation tissue at this point.  
Notably, CD31 is primarily absent in the muscularis propria.  By contrast, Ptgs2-/- mice 
(n=6) exhibit a transmural granulation tissue phenotype with degradation of the 
muscularis propria at day 6 demonstrating impaired healing of the wound.  CD31 positive 
cells throughout the wall of the colon suggest that the entirety of the organ in this location 
is made up of granulation tissue (Fig 3.1B).  In support of this interpretation, these 
deficient mice also lack a healthy muscularis propria as shown with SMA (Fig 3.1B).  
These results suggest that Ptgs2 is indeed important in healing in this discrete injury 
model. 
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Figure 3.1 
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Figure 3.1 Ptgs2 is required for and present during proper wound healing. 
WT C57Bl/6 or Ptgs2 -/- mice were injured by colonic biopsy and allowed to heal for 
six (A,B) or four (C-G) days before sacrifice and fixation with 4% paraformaldehyde.  
Seven micron sections were cut from frozen blocks and stained by indirect 
immunofluorescence and Hoechst dye.  Primary antibodies used were anti-SMA (A,B, 
red), anti-CD31 (A,B, red; D, green), anti-β-catenin (A,B, green), anti-Ptgs2 (C-G, red), 
anti-CD45 (E, green), anti-CD44 (F, green), or anti-CD29 (G, green).  Parenthesis 
(A,B) denotes area of muscularis propria in CD31-sections.  Parenthesis marks 
muscularis propria.  Arrowheads denote Ptgs2-positive cells that are enlarged to the 
right. 
 
Ptgs2-positive cells in the wound bed are probable MSCs 
As Ptgs2 seemed to be important in proper wound healing, we performed 
immunofluorescence using a specific Ptgs2 antibody in order to identify cells that may be 
the source of this gene within the wounded area.  A large, discrete population of cells 
expressing abundant Ptgs2 protein in the upper wound bed, directly apposed to the WAE 
cells, was easily detected (Fig. 3.1C).  In an attempt to identify the cell type(s) expressing 
Ptgs2, we co-stained sections with various lineage and surface markers.  The lack of co-
staining by CD31 or CD45 respectively demonstrated that these cells were neither of the 
endothelial nor hematopoietic lineage (Fig. 3.1D,E).  We did, however, observe co-
localization of Ptgs2 with both CD44 and CD29 (Fig. 3.1F,G).  This pattern of surface 
markers, in conjunction with high Ptgs2 expression, has been recognized previously in 
our lab and marks a population of cells known as mesenchymal stem cells.  We have 
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previously isolated MSCs from the colons of WT mice and used them to study the 
regulation of Ptgs2162.  In these earlier investigations, we showed that the regulation of 
Ptgs2 has a strong post-transcriptional component and thus hypothesized that a trans-
acting protein may be present in these cells capable of interacting with and regulating 
Ptgs2.  Performing a gene ontology analysis as previously reported162, we identified a 
number of candidate mRNA binding proteins, specifically HuR, CUGbp1, CUGbp2, 
Rbms3, Rbpms, Rbm3, and Imp1, as exhibiting preferential expression in colonic MSCs 
and screened these genes to identify a novel trans-acting factor that may be playing a role 
in the regulation of Ptgs2 and consequently in the healing of colonic biopsy injury. 
We screened these mRNA binding candidates by shRNA-mediated knockdown of the 
gene in cMSCs in vitro and observation of the effect of gene loss on Ptgs2 expression 
(Table 1).  We focused further investigations on insulin-like growth factor 2 binding 
protein 1 (Igf2bp1 or Imp1) because, while it has been highly studied as an mRNA 
binder95-97, interaction with Ptgs2 has never been reported.  Imp1 exhibits oncofetal 
expression, i.e. it is high during development, especially around day 12.5 in mice87, and is 
also upregulated in various tissue specific cancers including colonic carcinoma, breast 
carcinoma, and melanoma81.  However, at least one investigation reported detection of 
Imp1 in the distal intestine and testis of adult mice88.  Despite intense efforts78,79, the 
target mRNA binding sequence of Imp1 has never been precisely defined and appears to 
be degenerate and affected by 3D structure of the transcript79.  Furthermore, while some 
targets are known, many remain to be elucidated.  In fact, in one study estimated that 
Imp1 may bind up to 3% of the transcriptome78.  Taken together, these published data 
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along with our knockdown screen strongly suggested that Imp1 would be a worthwhile 
gene on which to focus for a potential novel function in regulating Ptgs2. 
  
Table 1 
Gene Knocked 
Down Knockdown achieved Ptgs2 fold change 
HuR -20 -3 
CUGbp2 -30 -8 
CUGbp1 -11 2.5 
Rbms3 -35 -3.5 
Rbm3 -9 -2 
Rbpms -12 -1.5 
Igf2bp1 -7 -5 
 
Table 1 Effect of decreased mRNA binding protein candidates on Ptgs2 expression. 
Annotated mRNA binding protein candidates were identified by a cutoff of 2 fold 
preferential expression in cMSCs vs. bmMSCs on global gene array analysis.  shRNAs 
specific for the candidates or control shRNA were transfected into HEK293T cells 
along with lentiviral packaging vectors to produce lentivirus that was then used to 
infect cMSCs in culture.  After 1-2 passages, expression of the targeted gene and Ptgs2 
were assessed with qRT-PCR.  Values reflect the strongest effect on Ptgs2 expression.  
Control shRNA produced no more than a -1.5 fold change in Ptgs2 mRNA. 
 
Imp1 protein interacts with Ptgs2 mRNA in the cellular environment. 
In order to observe whether Imp1 and Ptgs2 interact within the physiological cell 
environment, a (3X)FLAG-tagged Imp1 construct was created and driven by a CMV-
promoter in NIH3T3 cells.  The FLAG-tagged construct was immunoprecipitated using a 
specific antibody for FLAG, and the protein was eluted from the pellet specifically by 
competition with 3X FLAG peptide.  Total protein, eluate, and pellet fractions were 
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analyzed for protein content by immunoblot (Fig 3.2A) and associated RNA by 
quantitative RT-PCR (Fig 3.2B).  We hypothesized that if Imp1 does indeed interact with 
Ptgs2 mRNA, then this transcript should be specifically pulled down by Imp1 in the 
eluate and pellet fractions of the immunoprecipitation procedure.  As a control, we 
observed an 18S RNA abundance ratio in transfected vs. untransfected cells of near 1.0 in 
all fractions.  However, while the Ptgs2 abundance ratio was approximately 1.0 in the 
total protein fraction, this ratio was significantly increased in both the eluate and pellet 
fraction (Fig 3.2B).  These data demonstrated that Imp1-FLAG must specifically interact 
with Ptgs2 thereby enriching Ptgs2 in these fractions.  Similarly, two FLAG-tagged 
deletion mutants of Imp1 containing either the four C-terminal KH domains or the two N-
terminal RRM domains were also tested (Fig 3.2C).  We observed that KH-FLAG 
similarly enriched Ptgs2 while RRM-FLAG did not (Fig 3.2D).  The specific pull-down 
of Ptgs2 was thus neither an artifact of the transfection protocol nor the FLAG tag.  The 
mutant data suggested that the functional interaction between Imp1 and Ptgs2 RNA 
resides in the KH domains though the strength or frequency may be decreased in the 
absence of the full-length protein.  We concluded that Imp1 is indeed capable of 
interacting with Ptgs2 RNA in the cellular environment. 
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Figure 3.2 
 
Figure 3.2 Imp1 interacts physiologically with Ptgs2 mRNA. 
NIH3T3 cells were transiently transfected with Imp1-FLAG, KH-FLAG, or RRM-
FLAG, crosslinked with 300mJ 254nm UV, and lysed.  Cell lysates were 
immunoprecipitated using M2 anti-FLAG conjugated agarose beads, and protein and 
RNA were isolated from different fractions.  (A) Immunoblot with anti-FLAG-HRP 
showing expression of Imp1-FLAG and successful pulldown and elution of the protein.  
(B) Quantitative RT-PCR graph of 18S and Ptgs2 RNA measured in the various 
fractions during immunoprecipitation baselined to untransfected control.  (C) 
Immunoblot with anti-FLAG-HRP as in (A) including transient transfection and 
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immunoprecipitation of KH-FLAG and RRM-FLAG.  (D) Quantitative RT-PCR graph 
of 18S and Ptgs2 RNA measured in the total and pellet fractions during 
immunoprecipitation baselined to untransfected control.  Immunoblots are 
representative of at least 3 individual experiments and qRT-PCR graphs include data 
from 3-4 individual experiments.  Abbreviations: T, total protein; E, eluate; P, pellet.  
Statistics: unpaired student’s t test; n.s. not significant, *p<0.05, **p<0.01. 
 
Imp1 expression is increased in the wound bed and co-localizes with Ptgs2 expression. 
After demonstrating Imp1 and Ptgs2 interaction, we investigated whether Imp1 plays 
a role in vivo in the colonic biopsy injury model.  Measurement of Ptgs2 and Imp1 
expression in the wound bed compared to adjacent normal mucosa by qRT-PCR revealed 
strong upregulation of both genes (Fig. 3.3A), demonstrating that expression of Imp1 
coincided in place and time with Ptgs2 upregulation.  Notably, another well-known 
binder of Ptgs2 mRNA, CUGbp2, did not show similar upregulation.. 
We next assessed whether Imp1 was found in the Ptgs2-positive wound bed stromal 
cells.  Co-immunofluorescence was performed using antibodies for Imp1 and Ptgs2.  In 
agreement with our expectations following the in vitro pull-down experiments and in vivo 
RNA expression data, we found that Imp1 and Ptgs2 proteins were indeed located in the 
same cells in the upper portion of the wound bed (Fig 3.3B).  Quantitatively, we have 
observed that approximately 30% of Ptgs2-positive cells are also Imp1-positive while all 
Imp1-positive cells are also Ptgs2-positive (Fig 3.3C).  These data suggest that the 
presence of Imp1 may actually mark a specific type of Ptgs2-positive cell.  Alternatively, 
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in some cells, Imp1 may have been down-regulated below detectable levels while Ptgs2 
remains more strongly expressed within the time frame observed. 
 
Figure 3.3 
 
Figure 3.3 Imp1 is expressed in Ptgs2-expressing wound bed stromal cells. 
(A) Quantitative RT-PCR graph showing relative RNA abundance of Imp1, CUGbp2, 
and Ptgs2 in biopsy injured mucosa compared to uninjured mucosa.  (B) Indirect co-
label immunofluorescence of the wound bed using rabbit anti-Ptgs2 and goat anti-Imp1.  
Mice were sacrificed two days following colonic biopsy wounding, transfused with 4% 
paraformaldehyde and tissues processed for immunofluorescence. Yellow arrowhead 
depicts representative co-labeled cells in upper right enlargement.  Red arrowhead 
depicts single-label Ptgs2-positive cell in lower right enlargement. (C) Venn diagram 
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depicting the percentage of Ptgs2-positive cells in the wound bed that is also Imp1-
positive and the percentage of Imp1-positive cells that is also Ptgs2-positive.   
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Chapter 3: Discussion 
Mechanisms of Ptgs2-/- colonic biopsy phenotype 
We observed transmural granulation tissue at the site of colonic biopsy wounding by 
CD31 staining rather than intact healthy tissue layers such as the muscularis propria 
normally present and visualizable by SMA.  It is likely that this degradation of tissue and 
replacement by granulation tissue occurs due to the overactivity of the immune response 
in the absence of modulatory signaling from Ptgs2 mediators.  Furthermore, we have 
noted that the overlying WAE cells do not seem to be fully formed in Ptgs2-/-.  If the 
integrity of this layer is compromised, bacteria and other antigens may infiltrate the 
wound and further enhance the inflammatory response.  The specific effects of Ptgs2 
expression on the healing of colonic biopsy injury remain to be precisely elucidated.  
Prostaglandins, as the downstream products of Ptgs2 expression and activity, are likely to 
be playing at least a partial role in colonic biopsy healing.  We are currently investigating 
the timing of secretion of these mediators and whether the exogenous addition of specific 
prostaglandins, such as PGE2 or PGI2, may aid in healing. 
Imp1 as a marker 
We have described a population of stromal cells within the wound bed of colonic 
biopsy injured mice that express both Ptgs2 and Imp1.  The recognition of Imp1 
expression in this discrete subset of stromal cells during healing in adult tissues 
demonstrates the potential usefulness of Imp1 as a novel cell marker.  Fibroblasts are a 
poorly defined cell type so-called primarily due to their morphology alone, though the 
idea that different subsets exist is widely-accepted163.  However, the lack of defined 
markers specific to their identity and/or function hampers the classification of specific 
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populations of fibroblasts and their unique functions.  In our injury model, we have found 
Imp1 expression confined to a unique population of stromal cells in both time and space.  
Imp1 may thus serve as a marker of this subset.  Targeting this cell population genetically 
by Imp1 driven genetic tools could prove valuable in the definition and functional 
description of a unique subset of fibroblasts. 
Imp1 expression and function in the adult 
The observations herein also raise interesting questions as to the role of Imp1 in the 
adult animal.  Considering the common overexpression of Imp1 and Ptgs2 in various 
cancers, it would be worthwhile to investigate whether these two genes are correlated 
both in presence and in level of expression in the same oncologic samples.  Such 
descriptive studies could help precisely define different cancer subtypes from common 
tissues of origin as well as develop directed targets that may have fewer side effects than 
more generic inhibitors of Ptgs2. 
Furthermore, recent data detailing Imp1 interactions with viral RNAs98,99 
demonstrates the need for understanding the relevance of Imp1 expression in vivo.  The 
ability of Imp1 to increase replication of HCV as well as the presence of Imp1 in the HIV 
ribonucleoprotein complex in cells raises interesting questions.  Is Imp1 expressed at 
sufficient levels in the adult mammal in certain cell types susceptible to these viruses?  
Would the loss of this mRNA binding protein decrease the infectivity of the virus in 
whole organisms?  Most expression studies of Imp1 have been whole organism- or 
organ-oriented and thus small populations of cells expressing the gene could easily have 
been overlooked or diluted out in samples.  The answers to the questions posed will 
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require detailed expression studies within adult mammals, especially of cells known to be 
targeted by HIV or HCV virus. 
No studies to date report upregulation or visualization of Imp1 in wounded or healing 
tissue within the context of the organism.  The reported role of Ptgs2 in other models of 
injury in the lung and other tissues164,165 and the newly demonstrated interaction between 
Imp1 protein and Ptgs2 mRNA provide the tantalizing proposition that Imp1 expression 
may be found in many other injury models.  Might Imp1 expression in injury and healing 
be a generalizable phenomenon?  Histochemical and expression analysis of stromal 
tissues involved in injury and repair of other organs holds the potential of uncovering 
discrete Imp1 expression.  These studies may reveal a new role of Imp1 in the adult 
mammal in addition to the well-recognized correlation in cancer. 
Summary 
Ptgs2 expression and function are required for the proper response to colonic biopsy 
injury, a localized physical insult resulting in inflammation and subsequent tissue 
regeneration.  Its expression correlates with the expression of the mRNA binding protein 
Imp1 that can interact with Ptgs2 mRNA within the cellular environment.  This novel 
interaction of Imp1 and Ptgs2 as well as their common localization in wounded tissue 
highlights the need for further exploration of this novel relationship and may reveal a 
more generalizable role of Imp1 in adult tissue. 
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CHAPTER 4 
 
Summary and Future Directions 
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Chapter 4: Abstract 
The role of Ptgs2 and its downstream synthetic products in colonic injury has been 
well-documented.  The studies detailed in this thesis sought to uncover and define the 
mechanisms involved in the regulation of this important enzyme and focused on the post-
transcriptional regulation of this gene.  While the transcriptional regulation of Ptgs2 has 
been a focus of many investigations due to its recognized upregulation downstream of 
macrophage activation in inflammation, the post-transcriptional regulation may be more 
relevant in homeostasis in cells that constitutively express the gene.  We have shown that 
Ptgs2 post-transcriptional regulation can be mediated by Fgf9 signaling through Erk 
activation and CUGbp2 stabilization.  In addition, the mRNA binding protein Imp1 can 
also interact with Ptgs2, and loss of expression of this gene results in decreased Ptgs2.  
Notably, these various mechanisms of Ptgs2 post-transcriptional regulation may be 
important in homeostasis, response to injury, and healing. 
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Chapter 4: Summary of the Thesis and Future Directions 
Interactive roles of multiple mRNA binders on Ptgs2 
It has become more widely recognized that mRNA transcripts are generally found not 
free-floating in the cytoplasm but bound and organized in larger structures called RNPs 
or ribonucleoproteins166.  Ptgs2 can be bound by a number of proteins167, and this thesis 
demonstrates that Imp1 is a new addition to the list of mRNA interactors.  The identities 
and interactions among these various proteins must be fully understood in order to create 
an accurate illustration of the overall regulation of Ptgs2 at the post-transcriptional level. 
The most highly-studied sequence within the Ptgs2 transcript that is a target for 
mRNA binders is the ARE (AUUUA) signature.  This sequence is degenerate in that it is 
present in a number of different mRNA transcripts.  Indeed, the presence of AREs in 
many inflammatory and anti-inflammatory transcripts upregulated by TNFα stimulation 
help control the timing of the expression of these genes168.  How then is regulation of the 
transcript accomplished differentially from other inflammatory genes?  It is conceivable 
that cells may employ a number of different proteins targeted to different RNA sequences 
that would allow for more precise control of stability, translation, and even localization of 
Ptgs2 independent of other ARE-containing transcripts.  Our data, as well as that of 
others167, demonstrates that expression of Ptgs2 can be affected by a number of different 
mRNA binding proteins.  A more complete understanding of the interaction of transcripts 
and binding proteins will elucidate the mechanisms underlying control of one specific 
transcript post-transcriptionally. 
A goal yet to be attained is an accurate knowledge of the interactions of the various 
proteins and their transcripts, including but certainly not limited to Ptgs2.  What is the 
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stoichiometry and in which circumstances are certain binders required?  Some insight has 
been provided into these sorts of questions in the case of Ptgs2 with proof of interaction 
between various mRNA binding proteins by co-immunoprecipitation78,169.  Interaction of 
other binding proteins of Ptgs2, specifically HuR and Rbm3, has also been demonstrated 
using a yeast two hybrid system170.  Descriptive and functional studies investigating these 
protein-protein and likely protein-protein-RNA interactions will facilitate our ability to 
predict and understand the intricacies of post-transcriptional regulation. 
This work also raises the very simply stated question: Can Imp1 and CUGbp2 interact 
with Ptgs2 simultaneously?  While CUGbp2 and HuR are both able to bind to Ptgs2, it 
seems that different circumstances allow for more productive or greater affinity binding 
of one or the other to their common ARE target sequence in the 3' UTR of Ptgs2.  What 
is the role of Imp1 in these various circumstances?  Is Imp1 capable of interacting with 
Ptgs2 simply whenever the protein is present or is this interaction mediated by certain 
conditions and the signaling state within the cell?  To begin these investigations, co-
immunoprecipitation experiments of the protein and of a biotinylated Ptgs2 RNA probe 
can be performed.  These questions must be answered to address the hypothesis that Imp1 
and CUGbp2 cooperate in the precise regulation specifically of Ptgs2. 
One last line of inquiry stemming from the findings of this thesis is how exactly Ptgs2 
is destabilized.  As briefly mentioned in Chapter 3, CUGbp1 knockdown results in an 
increase in Ptgs2 expression; however, CUGbp1 has never been reported to affect or bind 
Ptgs2 mRNA.  Considering the high degree of similarity of CUGbp2 and CUGbp1, it is 
likely that they may compete for binding of the same sequence of Ptgs2 mRNA.  Could it 
be that in starvation conditions, the affinity of CUGbp2 for the ARE is diminished thus 
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allowing access of the transcript to CUGbp1?  Binding of CUGbp1 mediates enhanced 
degradation of the targeted mRNA171 by deadenylation.  Experiments designed to 
investigate the relative affinities and effects of CUGbp1 and CUGbp2 would test the 
hypothesis that CUGbp2 out-competes CUGbp1 during normal conditions while under 
alternate conditions, such as starvation, CUGbp1 binding relative to CUGbp2 increases, 
resulting in decreased Ptgs2 due to an increased rate of RNA degradation. 
Thus, many further intriguing lines of investigation into the various roles and 
interactions of Ptgs2 trans-acting factors are suggested by the experimental findings 
herein. 
Roles of mRNA binding protein phosphorylation. 
It has been demonstrated that, in at least one interaction of Imp1 with mRNA, 
tyrosine phosphorylation controls post-translational Imp1 activity97.  Considering the 
rapidity with which Ptgs2 is lost in starvation, the possibility that phosphorylation is 
important in the pathways regulating Ptgs2 is high as this post-translational change can 
have rapid effects on function.  This work demonstrates that activation of Erk by 
phosphorylation downstream of Fgf9 seems to act in the stability of Ptgs2.  It has already 
been demonstrated that CUGbp2 activity can be affected by tyrosine phosphorylation30, 
and our results suggest that there is likely a serine/threonine phosphorylation that may 
also play a role downstream of Erk.  This remains to be investigated. 
Whether phosphorylation of newly-identified Ptgs2 regulator Imp1 is important its 
control of Ptgs2 must also be investigated in order to understand the mechanism of 
activity.  Phosphorylation of Imp1 can affect its functional activity in binding to β-actin 
mRNA97.  We also have found evidence that suggests that phosphorylation may play a 
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role in Imp1 activity.  Visualization of Imp1 on immunoblot using a commercially 
available goat polyclonal antibody demonstrates a shift in the band upon starvation 
suggesting that some post-translational modification such as phosphorylation has been 
altered in these conditions.  Detection of the protein by another antibody, a mouse 
monoclonal, is complicated by its nonspecific detection of a band in fetal bovine serum 
of a similar size to Imp1.  However, starvation allows removal of this band.  Phosphatase 
treatment for 15min using calf intestinal phosphatase (CIP) of cell lysates was performed 
to begin to investigate these observations.  Treatment was monitored using Gapdh and 
pErk to confirm phosphatase activity.  We found that CIP and not buffer alone results in 
loss of detection of Imp1 by this mouse monoclonal antibody while a band is still 
detected by the goat polyclonal (Fig 4.1A).  A possible explanation for this could be that 
the mouse monoclonal shows specificity for a phosphorylated form of Imp1.  This 
remains to be further investigated.  We have also asked whether starvation of cells results 
in differential interaction between Imp1 protein and Ptgs2 mRNA using our Imp1-FLAG 
pull-down protocol.  Pull-down fractions of cells either starved 25min or normally treated 
showed no significant difference in enrichment of Ptgs2 (Fig 4.1B).  This suggests that 
the Ptgs2 transcripts that are still present after this starvation protocol remain associated 
with Imp1.  It could be that Ptgs2 can be degraded while still associated with Imp1 or that 
Ptgs2 is immediately degraded upon dissociation from Imp1.  These questions must be 
tested in order to understand the mechanism of Ptgs2 degradation and of Imp1 interaction 
with Ptgs2. 
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Figure 4.1 
 
Figure 4.1 Imp1 phosphorylation and Ptgs2 interactions in 0% serum. 
(A) Immunoblots of CIP-treated cell lysates demonstrating that treatment affects the 
detection of Imp1 by a mouse monoclonal antibody.  Fetal bovine serum alone or 5min 
serum starved cells were lysed in RIPA with protease inhibitors only, and aliquots were 
treated either with buffer alone or with CIP for 15min at 37ºC.  Antibodies used were 
mouse monoclonal anti-Imp1, goat polyclonal anti-Imp1, anti-pErk, and anti-Gapdh 
and were indirectly visualized by secondary HRP-conjugated antibodies.  (B) qRT-PCR 
graph of 18S and Ptgs2 RNA measured in the total, eluate, and pellet fractions of the 
immunoprecipitation protocol baselined to untransfected control.  Control and 
transfected cells were either starved (0%) or not (10%) for 25min prior to IP protocol. 
 
Control of Imp1 regulation 
The regulation involved in Imp1 expression in colonic injury has not been determined.  
Identification of the extracellular signal(s) capable of upregulating Imp1 during injury 
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within the wound bed would add to the overall understanding of the biology of both Imp1 
and of wound healing.  The signals involved could be singular or multiple.  One or 
multiple soluble factors could be required such as the many growth factors found within 
the wound bed or a precise cytokine signature from the local immune cells.  Membrane-
bound signals may also play a role.  Indeed, the discrete area of expression of Imp1 in the 
wound bed suggests that such factors may be important either from neighboring cells or 
from the extracellular matrix of the wound bed.  It does appear to be likely that multiple 
factors are involved based on data acquired thus far. 
We have shown multiple soluble factors that, singularly acting on either cMSCs or 
NIH3T3 cells, have no discernable effect on Imp1 expression.  These include Wnt3a, 
BMP4 and BMP8A, TNFα, IFNγ, LPS, and EGF (Fig 4.2 and data not shown).  It is 
interesting to note that, while others have shown that β-catenin activation can increase 
Imp1 expression in different circumstances100, activation of the same pathway by 
canonical Wnt signal has no effect on cMSC or NIH3T3 cell expression of Imp1 after 2-3 
hours. 
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Figure 4.2 
 
Figure 4.2 Imp1 regulation in cMSCs is not affected by Wnt, TNFα, or IFNγ. 
Graphs depicting fold change of genes measured by qRT-PCR.  (A)  Fold change of 
iigp and Imp1 in cells treated with IFNγ, TNFα, or both.  (B)  Fold change of axin2 and 
Imp1 in cells treated with Wnt3a, Rspondin, or both.  Error bars represent standard 
deviation. 
 
One potential source of this signal is the epithelium surrounding the wound bed, with 
the overlying WAE cells as the strongest candidates due to the close localization of Imp1 
positive cells.  We have isolated RNA from the WAE cells, adjacent epithelium, and 
normal epithelium by laser capture microscopy and analyzed this material by microarray 
(unpublished, C. Luo).  This data may provide candidates for further studies into the 
regulation of Imp1 of soluble and/or membrane-bound basis. 
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Imp-1 is not simply an oncofetal protein 
The findings described herein show that Imp1 cannot simply be regarded as an 
oncofetal protein. We have shown that it is upregulated in at least one injurious 
circumstance, and others have shown that Imp1 is expressed under homeostatic 
conditions in the mouse88.  It is logical to hypothesize that, with the demonstrated ability 
of Imp1 to interact with Ptgs2 mRNA and the documented necessity of Ptgs2 within 
various colonic injury models14,20,23, that the upregulation of Imp1 partially mediates 
increased Ptgs2 expression.  We also witness preferential expression of Imp1 in cMSCs 
versus bmMSCs suggesting that Imp1 is expressed in the normal colonic Ptgs2-
expressing stromal cell.  It may indeed be that the expression of Imp1 by qRT-PCR 
reported by others in the adult colon is found primarily within the Ptgs2-expressing 
stromal cell type.  Imp1 presents itself thus as a strong candidate for lineage specification 
of this relatively undefined cell type.  Up to this point, Ptgs2 expression has been the 
strongest and most specific marker of this mesenchymal stem cell stromal cell type in the 
colonic mesenchyme.  However, Ptgs2 as a marker provides considerable complications 
as it can also be upregulated in myeloid-derived hematopoietic cells in inflammation.  
Imp1 may be a new, more specific marker of this lineage.  Creation of a mouse in which 
lacZ or GFP is expressed by the Imp1 promoter may provide new insight into the origin, 
lineage, and movement of these cells. 
Furthermore, the role of Imp1 within the adult animal requires further definition.  
While a global knockout of Imp1 has been created94, the fact that Imp1 is highly 
expressed during embryogenesis complicates the interpretation of possible Imp1 
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functions in the adult.  The ideal tool to investigate the potential roles of Imp1 during 
post-natal life is a mouse expressing a floxed Imp1 gene.  This mouse could then be bred 
to various strains that express Cre under different promoters, allowing for the 
investigation of the role of Imp1 in specific cell types or tissues.  Alternatively, and 
potentially more powerfully, this mouse could be bred to an inducible Cre in order to 
remove Imp1 at specific stages in the adult followed by investigation of the effect of such 
deletion.  For example, Imp1 could be deleted in the mouse just prior to colonic biopsy 
which would allow for specific investigation of the role of Imp1 in this injury model.  
Further defining the role of Imp1 is essential not only to uncover the potential biological 
roles of Imp1 but also to understand the precise function of this gene in injury. 
The role of Ptgs2 in acute injury 
The mechanistic progression underlying the observed phenotype of transmural 
granulation tissue in colonic endoscopic biopsy in Ptgs2-/- mice remains to be elucidated 
and may be multi-faceted.  One strong possibility is that the inflammatory response 
occurs unchecked by the normal upregulation of Ptgs2 and consequent secretion of 
prostaglandins.  A careful count of the ratio of neutrophils and macrophages at the early 
stages could help to address this issue as well as measurement of local and serum 
inflammatory cytokines.  It has been shown that M2 phenotype of macrophages and Th2 
cytokines are important in healing15; thus, determination of the phenotype of 
macrophages present in the wound of Ptgs2-/- mice could demonstrate increased 
inflammatory state.  Assessment of the level of microbial infiltration in the wound bed is 
also warranted.  It appears that the integrity of the epithelial layer in Ptgs2-/- may be 
compromised.  Lumenal bacterial populations may therefore invade the wound bed, 
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which could also contribute to a differential or greater immune response compared to WT 
mice. 
Another interesting line of investigation involves testing whether the observed 
transmural granulation tissue phenotype can be rescued by exogenous addition of specific 
mediators.  Two of the best possibilities are a long-lasting PGE2 (dmPGE2)13 or 
hematopoietic cells from WT mice that express Ptgs2. 
Finally, the required cellular source of Ptgs2 remains to be rigorously demonstrated.  
It is highly likely that Ptgs2 must be expressed by the observed stromal cell population in 
the wound bed.  A few new genetic tools must be created in order to reliably test this 
hypothesis.  While a floxed Ptgs2 mouse has been made172 and used for similar cell-
specific studies173, a stop flox Ptgs2 driven by a ubiquitous promoter would allow 
targeting of Ptgs2 expression to specific cell types.  The cellular source of Ptgs2 can then 
be tested both by lineage-specific knockout as well as by lineage-specific expression of 
Ptgs2.   One potential experiment involves specific Ptgs2 knockout of the mesenchyme, 
along with expression of Ptgs2 in hematopoietic cells either genetically-driven or by bone 
marrow chimera.  Alternatively, creation of a knock-in Imp1-driven Cre-IRES-GFP may 
be valuable as it seems to be capable of knocking out Ptgs2 in a very specific subset of 
cells.  Intriguingly, this last model would allow for Ptgs2 expression in all other cells 
except those expressing Imp1 while the GFP would allow for visualization of the cells 
expressing Imp1 and therefore lacking Ptgs2. 
Imp1 as a marker for MSC/ fibroblast 
Fibroblasts are a highly heterogeneous population of cells found in every organ.  
However, referring to all morphologically fibroblastic cells as fibroblast is akin to 
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referring to all T cells, B cells, NK cells, macrophages, etc as immune cells.  It lacks 
precision.  This fact has become more recognized as fibroblasts have begun to be sorted 
into somewhat smaller subsets such as ‘tumor stromal cell’ or, as is of interest here, 
‘MSC’163.  A complete understanding of the various types of fibroblasts and the 
potentially differing activities and functions is hindered by a deficiency in precise 
markers such as those that have been recognized in other cellular types.  The finding that 
Imp1 is expressed in injury in a specific subset of stromal cells suggests a new marker of 
an as-yet-undefined fibroblast population.  Creation of an Imp1 reporter mouse (or, as 
mentioned above, Cre-IRES-GFP for greater flexibility of use) may allow lineage tracing 
of these cells, definition of a fibroblast subset, and contribute to the general field of 
fibroblast biology. 
Final Summary 
The work contained in this thesis provides a deeper understanding of post-
transcriptional Ptgs2 regulation and places these observations within the context of 
multiple forms of colonic injury.  The applicability of these findings to Ptgs2 in other 
injury systems or in other cell types may prove to be useful as well, especially in 
understanding the constitutive expression of this gene.  Further investigations into the 
mechanisms driven by Ptgs2 involved in mediating colonic injury will be aided by this 
additional knowledge of the activity of various mRNA binding proteins.  Most notably, 
this work uncovers the novel interaction of Imp1 and Ptgs2 and provides intriguing 
observations on the likely role this may play in physical colonic injury.  Future studies 
will benefit from building upon these findings in order to create a complete mechanistic 
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picture of Ptgs2 regulation and its function in colonic injury, and hopefully, will aid the 
medical field in creation of targeted diagnostic tools and treatment protocols. 
 
  
 96
References 
1. Walker, M.R. & Stappenbeck, T.S. Deciphering the 'black box' of the intestinal stem 
cell niche: taking direction from other systems. Curr. Opin. Gastroenterol 24, 115-
120 (2008). 
2. de Santa Barbara, P., van den Brink, G.R. & Roberts, D.J. Development and 
differentiation of the intestinal epithelium. Cell. Mol. Life Sci 60, 1322-1332 (2003). 
3. Sancho, E., Batlle, E. & Clevers, H. Live and let die in the intestinal epithelium. 
Curr. Opin. Cell Biol 15, 763-770 (2003). 
4. Korinek, V. et al. Two members of the Tcf family implicated in Wnt/beta-catenin 
signaling during embryogenesis in the mouse. Mol. Cell. Biol 18, 1248-1256 (1998). 
5. Pinto, D., Gregorieff, A., Begthel, H. & Clevers, H. Canonical Wnt signals are 
essential for homeostasis of the intestinal epithelium. Genes Dev 17, 1709-1713 
(2003). 
6. Winesett, M.P., Ramsey, G.W. & Barnard, J.A. Type II TGF(beta) receptor 
expression in intestinal cell lines and in the intestinal tract. Carcinogenesis 17, 989-
995 (1996). 
7. Jensen, J. et al. Control of endodermal endocrine development by Hes-1. Nat. Genet 
24, 36-44 (2000). 
8. Bjerknes, M. & Cheng, H. Neurogenin 3 and the enteroendocrine cell lineage in the 
adult mouse small intestinal epithelium. Dev. Biol 300, 722-735 (2006). 
9. Sukegawa, A. et al. The concentric structure of the developing gut is regulated by 
Sonic hedgehog derived from endodermal epithelium. Development 127, 1971-1980 
(2000). 
10. van den Brink, G.R. Hedgehog signaling in development and homeostasis of the 
gastrointestinal tract. Physiol. Rev 87, 1343-1375 (2007). 
11. Jurjus, A.R., Khoury, N.N. & Reimund, J. Animal models of inflammatory bowel 
disease. J Pharmacol Toxicol Methods 50, 81-92 (2004). 
12. Okayasu, I. et al. A novel method in the induction of reliable experimental acute and 
chronic ulcerative colitis in mice. Gastroenterology 98, 694-702 (1990). 
13. Pull, S.L., Doherty, J.M., Mills, J.C., Gordon, J.I. & Stappenbeck, T.S. Activated 
macrophages are an adaptive element of the colonic epithelial progenitor niche 
necessary for regenerative responses to injury. Proc. Natl. Acad. Sci. U.S.A 102, 99-
104 (2005). 
14. Brown, S.L. et al. Myd88-dependent positioning of Ptgs2-expressing stromal cells 
maintains colonic epithelial proliferation during injury. J. Clin. Invest 117, 258-269 
(2007). 
15. Seno, H. et al. Efficient colonic mucosal wound repair requires Trem2 signaling. 
Proc. Natl. Acad. Sci. U.S.A 106, 256-261 (2009). 
16. Wang, D., Mann, J.R. & DuBois, R.N. The role of prostaglandins and other 
eicosanoids in the gastrointestinal tract. Gastroenterology 128, 1445-1461 (2005). 
17. Dinchuk, J.E. et al. Renal abnormalities and an altered inflammatory response in 
mice lacking cyclooxygenase II. Nature 378, 406-409 (1995). 
18. Loftin, C.D., Tiano, H.F. & Langenbach, R. Phenotypes of the COX-deficient mice 
indicate physiological and pathophysiological roles for COX-1 and COX-2. 
Prostaglandins Other Lipid Mediat 68-69, 177-185 (2002). 
 97
19. Morham, S.G. et al. Prostaglandin synthase 2 gene disruption causes severe renal 
pathology in the mouse. Cell 83, 473-482 (1995). 
20. Riehl, T.E., Newberry, R.D., Lorenz, R.G. & Stenson, W.F. TNFR1 mediates the 
radioprotective effects of lipopolysaccharide in the mouse intestine. Am. J. Physiol. 
Gastrointest. Liver Physiol 286, G166-173 (2004). 
21. Tessner, T.G., Cohn, S.M., Schloemann, S. & Stenson, W.F. Prostaglandins prevent 
decreased epithelial cell proliferation associated with dextran sodium sulfate injury 
in mice. Gastroenterology 115, 874-882 (1998). 
22. Dey, I., Lejeune, M. & Chadee, K. Prostaglandin E2 receptor distribution and 
function in the gastrointestinal tract. Br. J. Pharmacol 149, 611-623 (2006). 
23. Kabashima, K. et al. The prostaglandin receptor EP4 suppresses colitis, mucosal 
damage and CD4 cell activation in the gut. J. Clin. Invest 109, 883-893 (2002). 
24. Barrett, J.C. et al. Genome-wide association defines more than 30 distinct 
susceptibility loci for Crohn's disease. Nat. Genet 40, 955-962 (2008). 
25. Newberry, R.D., McDonough, J.S., Stenson, W.F. & Lorenz, R.G. Spontaneous and 
continuous cyclooxygenase-2-dependent prostaglandin E2 production by stromal 
cells in the murine small intestine lamina propria: directing the tone of the intestinal 
immune response. J. Immunol 166, 4465-4472 (2001). 
26. Tsatsanis, C., Androulidaki, A., Venihaki, M. & Margioris, A.N. Signalling 
networks regulating cyclooxygenase-2. Int. J. Biochem. Cell Biol 38, 1654-1661 
(2006). 
27. Harper, K.A. & Tyson-Capper, A.J. Complexity of COX-2 gene regulation. 
Biochem. Soc. Trans 36, 543-545 (2008). 
28. Ishikawa, T., Jain, N.K., Taketo, M.M. & Herschman, H.R. Imaging 
cyclooxygenase-2 (Cox-2) gene expression in living animals with a luciferase 
knock-in reporter gene. Mol Imaging Biol 8, 171-187 (2006). 
29. Xu, K., Chang, C., Gao, H. & Shu, H.G. Epidermal growth factor-dependent 
cyclooxygenase-2 induction in gliomas requires protein kinase C-delta. Oncogene 
28, 1410-1420 (2009). 
30. Xu, K., Kitchen, C.M., Shu, H.G. & Murphy, T.J. Platelet-derived growth factor-
induced stabilization of cyclooxygenase 2 mRNA in rat smooth muscle cells 
requires the c-Src family of protein-tyrosine kinases. J. Biol. Chem 282, 32699-
32709 (2007). 
31. Tessner, T.G. et al. Basic fibroblast growth factor upregulates cyclooxygenase-2 in 
I407 cells through p38 MAP kinase. Am. J. Physiol. Gastrointest. Liver Physiol 284, 
G269-279 (2003). 
32. Fong, C.Y., Pang, L., Holland, E. & Knox, A.J. TGF-beta1 stimulates IL-8 release, 
COX-2 expression, and PGE(2) release in human airway smooth muscle cells. Am. J. 
Physiol. Lung Cell Mol. Physiol 279, L201-207 (2000). 
33. Dixon, D.A., Kaplan, C.D., McIntyre, T.M., Zimmerman, G.A. & Prescott, S.M. 
Post-transcriptional control of cyclooxygenase-2 gene expression. The role of the 3'-
untranslated region. J. Biol. Chem 275, 11750-11757 (2000). 
34. Cok, S.J. & Morrison, A.R. The 3'-untranslated region of murine cyclooxygenase-2 
contains multiple regulatory elements that alter message stability and translational 
efficiency. J. Biol. Chem 276, 23179-23185 (2001). 
35. Barreau, C., Paillard, L., Méreau, A. & Osborne, H.B. Mammalian CELF/Bruno-
 98
like RNA-binding proteins: molecular characteristics and biological functions. 
Biochimie 88, 515-525 (2006). 
36. Mukhopadhyay, D., Houchen, C.W., Kennedy, S., Dieckgraefe, B.K. & Anant, S. 
Coupled mRNA stabilization and translational silencing of cyclooxygenase-2 by a 
novel RNA binding protein, CUGBP2. Mol. Cell 11, 113-126 (2003). 
37. Murmu, N. et al. Dynamic antagonism between RNA-binding protein CUGBP2 and 
cyclooxygenase-2-mediated prostaglandin E2 in radiation damage. Proc. Natl. Acad. 
Sci. U.S.A 101, 13873-13878 (2004). 
38. Sureban, S.M. et al. Functional antagonism between RNA binding proteins HuR and 
CUGBP2 determines the fate of COX-2 mRNA translation. Gastroenterology 132, 
1055-1065 (2007). 
39. da Silva Meirelles, L., Chagastelles, P.C. & Nardi, N.B. Mesenchymal stem cells 
reside in virtually all post-natal organs and tissues. J. Cell. Sci 119, 2204-2213 
(2006). 
40. Friedenstein, A.J. et al. Precursors for fibroblasts in different populations of 
hematopoietic cells as detected by the in vitro colony assay method. Exp. Hematol 2, 
83-92 (1974). 
41. Pittenger, M.F. et al. Multilineage potential of adult human mesenchymal stem cells. 
Science 284, 143-147 (1999). 
42. Pereira, R.F. et al. Cultured adherent cells from marrow can serve as long-lasting 
precursor cells for bone, cartilage, and lung in irradiated mice. Proc. Natl. Acad. Sci. 
U.S.A 92, 4857-4861 (1995). 
43. Ferrari, G. et al. Muscle regeneration by bone marrow-derived myogenic 
progenitors. Science 279, 1528-1530 (1998). 
44. Dominici, M. et al. Minimal criteria for defining multipotent mesenchymal stromal 
cells. The International Society for Cellular Therapy position statement. 
Cytotherapy 8, 315-317 (2006). 
45. Aggarwal, S. & Pittenger, M.F. Human mesenchymal stem cells modulate 
allogeneic immune cell responses. Blood 105, 1815-1822 (2005). 
46. Ohtaki, H. et al. Stem/progenitor cells from bone marrow decrease neuronal death in 
global ischemia by modulation of inflammatory/immune responses. Proc. Natl. 
Acad. Sci. U.S.A 105, 14638-14643 (2008). 
47. Németh, K. et al. Bone marrow stromal cells attenuate sepsis via prostaglandin 
E(2)-dependent reprogramming of host macrophages to increase their interleukin-10 
production. Nat. Med 15, 42-49 (2009). 
48. Stagg, J. Immune regulation by mesenchymal stem cells: two sides to the coin. 
Tissue Antigens 69, 1-9 (2007). 
49. Chabannes, D. et al. A role for heme oxygenase-1 in the immunosuppressive effect 
of adult rat and human mesenchymal stem cells. Blood 110, 3691-3694 (2007). 
50. Djouad, F. et al. Mesenchymal stem cells inhibit the differentiation of dendritic cells 
through an interleukin-6-dependent mechanism. Stem Cells 25, 2025-2032 (2007). 
51. Ortiz, L.A. et al. Interleukin 1 receptor antagonist mediates the antiinflammatory 
and antifibrotic effect of mesenchymal stem cells during lung injury. Proc. Natl. 
Acad. Sci. U.S.A 104, 11002-11007 (2007). 
52. Augello, A. et al. Bone marrow mesenchymal progenitor cells inhibit lymphocyte 
proliferation by activation of the programmed death 1 pathway. Eur. J. Immunol 35, 
 99
1482-1490 (2005). 
53. Krampera, M. et al. Bone marrow mesenchymal stem cells inhibit the response of 
naive and memory antigen-specific T cells to their cognate peptide. Blood 101, 
3722-3729 (2003). 
54. Nauta, A.J. et al. Donor-derived mesenchymal stem cells are immunogenic in an 
allogeneic host and stimulate donor graft rejection in a nonmyeloablative setting. 
Blood 108, 2114-2120 (2006). 
55. Sudres, M. et al. Bone marrow mesenchymal stem cells suppress lymphocyte 
proliferation in vitro but fail to prevent graft-versus-host disease in mice. J. 
Immunol 176, 7761-7767 (2006). 
56. Ramasamy, R., Tong, C.K., Seow, H.F., Vidyadaran, S. & Dazzi, F. The 
immunosuppressive effects of human bone marrow-derived mesenchymal stem cells 
target T cell proliferation but not its effector function. Cell. Immunol 251, 131-136 
(2008). 
57. English, K., Barry, F.P., Field-Corbett, C.P. & Mahon, B.P. IFN-gamma and TNF-
alpha differentially regulate immunomodulation by murine mesenchymal stem cells. 
Immunol. Lett 110, 91-100 (2007). 
58. Ryan, J.M., Barry, F., Murphy, J.M. & Mahon, B.P. Interferon-gamma does not 
break, but promotes the immunosuppressive capacity of adult human mesenchymal 
stem cells. Clin. Exp. Immunol 149, 353-363 (2007). 
59. Liotta, F. et al. Toll-like receptors 3 and 4 are expressed by human bone marrow-
derived mesenchymal stem cells and can inhibit their T-cell modulatory activity by 
impairing Notch signaling. Stem Cells 26, 279-289 (2008). 
60. Pevsner-Fischer, M. et al. Toll-like receptors and their ligands control mesenchymal 
stem cell functions. Blood 109, 1422-1432 (2007). 
61. Karnoub, A.E. et al. Mesenchymal stem cells within tumour stroma promote breast 
cancer metastasis. Nature 449, 557-563 (2007). 
62. Qiao, L. et al. Suppression of tumorigenesis by human mesenchymal stem cells in a 
hepatoma model. Cell Res 18, 500-507 (2008). 
63. Lazennec, G. & Jorgensen, C. Concise review: adult multipotent stromal cells and 
cancer: risk or benefit? Stem Cells 26, 1387-1394 (2008). 
64. Picinich, S.C., Mishra, P.J., Mishra, P.J., Glod, J. & Banerjee, D. The therapeutic 
potential of mesenchymal stem cells. Cell- & tissue-based therapy. Expert Opin Biol 
Ther 7, 965-973 (2007). 
65. Crisan, M. et al. A perivascular origin for mesenchymal stem cells in multiple 
human organs. Cell Stem Cell 3, 301-313 (2008). 
66. Zhang, M. et al. SDF-1 expression by mesenchymal stem cells results in trophic 
support of cardiac myocytes after myocardial infarction. FASEB J 21, 3197-3207 
(2007). 
67. Humphreys, B.D. & Bonventre, J.V. Mesenchymal stem cells in acute kidney injury. 
Annu. Rev. Med 59, 311-325 (2008). 
68. Hayashi, Y. et al. Topical implantation of mesenchymal stem cells has beneficial 
effects on healing of experimental colitis in rats. J. Pharmacol. Exp. Ther 326, 523-
531 (2008). 
69. Hayashi, Y. et al. Topical transplantation of mesenchymal stem cells accelerates 
gastric ulcer healing in rats. Am. J. Physiol. Gastrointest. Liver Physiol 294, G778-
 100
786 (2008). 
70. Wang, Y., Deng, Y. & Zhou, G. SDF-1alpha/CXCR4-mediated migration of 
systemically transplanted bone marrow stromal cells towards ischemic brain lesion 
in a rat model. Brain Res 1195, 104-112 (2008). 
71. Ju, Y., Muneta, T., Yoshimura, H., Koga, H. & Sekiya, I. Synovial mesenchymal 
stem cells accelerate early remodeling of tendon-bone healing. Cell Tissue Res 332, 
469-478 (2008). 
72. Osiris Therapeutics Inc. | Clinical Trials - Prochymal® Clinical Trial Information 
for the Treatment of Crohn's Disease. at 
<http://www.osiris.com/clinical_prochymal_crohns.php> 
73. Steingen, C. et al. Characterization of key mechanisms in transmigration and 
invasion of mesenchymal stem cells. J. Mol. Cell. Cardiol 44, 1072-1084 (2008). 
74. Peng, L. et al. Comparative analysis of mesenchymal stem cells from bone marrow, 
cartilage, and adipose tissue. Stem Cells Dev 17, 761-773 (2008). 
75. Kulterer, B. et al. Gene expression profiling of human mesenchymal stem cells 
derived from bone marrow during expansion and osteoblast differentiation. BMC 
Genomics 8, 70 (2007). 
76. Yoo, H. et al. Production and characterization of monoclonal antibodies to 
mesenchymal stem cells derived from human bone marrow. Hybridoma (Larchmt) 
24, 92-97 (2005). 
77. Peroni, D. et al. Stem molecular signature of adipose-derived stromal cells. Exp. 
Cell Res 314, 603-615 (2008). 
78. Jønson, L. et al. Molecular composition of IMP1 ribonucleoprotein granules. Mol. 
Cell Proteomics 6, 798-811 (2007). 
79. Hafner, M. et al. Transcriptome-wide identification of RNA-binding protein and 
microRNA target sites by PAR-CLIP. Cell 141, 129-141 (2010). 
80. Nielsen, F.C., Nielsen, J., Kristensen, M.A., Koch, G. & Christiansen, J. 
Cytoplasmic trafficking of IGF-II mRNA-binding protein by conserved KH 
domains. J. Cell. Sci 115, 2087-2097 (2002). 
81. Yaniv, K. & Yisraeli, J.K. The involvement of a conserved family of RNA binding 
proteins in embryonic development and carcinogenesis. Gene 287, 49-54 (2002). 
82. Yisraeli, J.K. VICKZ proteins: a multi-talented family of regulatory RNA-binding 
proteins. Biol. Cell 97, 87-96 (2005). 
83. Ross, A.F., Oleynikov, Y., Kislauskis, E.H., Taneja, K.L. & Singer, R.H. 
Characterization of a beta-actin mRNA zipcode-binding protein. Mol. Cell. Biol 17, 
2158-2165 (1997). 
84. Havin, L. et al. RNA-binding protein conserved in both microtubule- and 
microfilament-based RNA localization. Genes Dev 12, 1593-1598 (1998). 
85. Deshler, J.O., Highett, M.I. & Schnapp, B.J. Localization of Xenopus Vg1 mRNA 
by Vera protein and the endoplasmic reticulum. Science 276, 1128-1131 (1997). 
86. Prokipcak, R.D., Herrick, D.J. & Ross, J. Purification and properties of a protein 
that binds to the C-terminal coding region of human c-myc mRNA. J. Biol. Chem 
269, 9261-9269 (1994). 
87. Nielsen, J. et al. A family of insulin-like growth factor II mRNA-binding proteins 
represses translation in late development. Mol. Cell. Biol 19, 1262-1270 (1999). 
88. Islam, S., Montgomery, R.K., Fialkovich, J.J. & Grand, R.J. Developmental and 
 101
regional expression and localization of mRNAs encoding proteins involved in RNA 
translocation. J. Histochem. Cytochem 53, 1501-1509 (2005). 
89. Ioannidis, P. et al. C-MYC and IGF-II mRNA-binding protein (CRD-BP/IMP-1) in 
benign and malignant mesenchymal tumors. Int. J. Cancer 94, 480-484 (2001). 
90. Ioannidis, P. et al. Expression of the RNA-binding protein CRD-BP in brain and 
non-small cell lung tumors. Cancer Lett 209, 245-250 (2004). 
91. Ross, J., Lemm, I. & Berberet, B. Overexpression of an mRNA-binding protein in 
human colorectal cancer. Oncogene 20, 6544-6550 (2001). 
92. Ioannidis, P. et al. 8q24 Copy number gains and expression of the c-myc mRNA 
stabilizing protein CRD-BP in primary breast carcinomas. Int. J. Cancer 104, 54-59 
(2003). 
93. Elcheva, I., Tarapore, R.S., Bhatia, N. & Spiegelman, V.S. Overexpression of 
mRNA-binding protein CRD-BP in malignant melanomas. Oncogene 27, 5069-
5074 (2008). 
94. Hansen, T.V.O. et al. Dwarfism and impaired gut development in insulin-like 
growth factor II mRNA-binding protein 1-deficient mice. Mol. Cell. Biol 24, 4448-
4464 (2004). 
95. Sparanese, D. & Lee, C.H. CRD-BP shields c-myc and MDR-1 RNA from 
endonucleolytic attack by a mammalian endoribonuclease. Nucleic Acids Res 35, 
1209-1221 (2007). 
96. Elcheva, I., Goswami, S., Noubissi, F.K. & Spiegelman, V.S. CRD-BP protects the 
coding region of betaTrCP1 mRNA from miR-183-mediated degradation. Mol. Cell 
35, 240-246 (2009). 
97. Hüttelmaier, S. et al. Spatial regulation of beta-actin translation by Src-dependent 
phosphorylation of ZBP1. Nature 438, 512-515 (2005). 
98. Zhou, Y., Rong, L., Lu, J., Pan, Q. & Liang, C. Insulin-like growth factor II mRNA 
binding protein 1 associates with Gag protein of human immunodeficiency virus 
type 1, and its overexpression affects virus assembly. J. Virol 82, 5683-5692 (2008). 
99. Weinlich, S. et al. IGF2BP1 enhances HCV IRES-mediated translation initiation via 
the 3'UTR. RNA 15, 1528-1542 (2009). 
100. Noubissi, F.K. et al. CRD-BP mediates stabilization of betaTrCP1 and c-myc 
mRNA in response to beta-catenin signalling. Nature 441, 898-901 (2006). 
101. Gu, W., Wells, A.L., Pan, F. & Singer, R.H. Feedback regulation between zipcode 
binding protein 1 and beta-catenin mRNAs in breast cancer cells. Mol. Cell. Biol 28, 
4963-4974 (2008). 
102. Gu, W., Pan, F. & Singer, R.H. Blocking beta-catenin binding to the ZBP1 promoter 
represses ZBP1 expression, leading to increased proliferation and migration of 
metastatic breast-cancer cells. J. Cell. Sci 122, 1895-1905 (2009). 
103. Eckburg, P.B. et al. Diversity of the human intestinal microbial flora. Science 308, 
1635-1638 (2005). 
104. Ley, R.E. et al. Obesity alters gut microbial ecology. Proc. Natl. Acad. Sci. U.S.A 
102, 11070-11075 (2005). 
105. Savage, D.C. Microbial ecology of the gastrointestinal tract. Annu. Rev. Microbiol 
31, 107-133 (1977). 
106. Cliffe, L.J. et al. Accelerated intestinal epithelial cell turnover: a new mechanism of 
parasite expulsion. Science 308, 1463-1465 (2005). 
 102
107. Chang, W.W. & Leblond, C.P. Renewal of the epithelium in the descending colon 
of the mouse. I. Presence of three cell populations: vacuolated-columnar, mucous 
and argentaffin. Am. J. Anat 131, 73-99 (1971). 
108. Kim, C.H. Chemokine-chemokine receptor network in immune cell trafficking. 
Curr. Drug Targets Immune Endocr. Metabol. Disord 4, 343-361 (2004). 
109. Allgayer, H., Deschryver, K. & Stenson, W.F. Treatment with 16,16'-dimethyl 
prostaglandin E2 before and after induction of colitis with trinitrobenzenesulfonic 
acid in rats decreases inflammation. Gastroenterology 96, 1290-1300 (1989). 
110. Morteau, O. et al. Impaired mucosal defense to acute colonic injury in mice lacking 
cyclooxygenase-1 or cyclooxygenase-2. J. Clin. Invest 105, 469-478 (2000). 
111. Tessner, T.G., Muhale, F., Riehl, T.E., Anant, S. & Stenson, W.F. Prostaglandin E2 
reduces radiation-induced epithelial apoptosis through a mechanism involving AKT 
activation and bax translocation. J. Clin. Invest 114, 1676-1685 (2004). 
112. North, T.E. et al. Prostaglandin E2 regulates vertebrate haematopoietic stem cell 
homeostasis. Nature 447, 1007-1011 (2007). 
113. Stanley, E.R., Cifone, M., Heard, P.M. & Defendi, V. Factors regulating 
macrophage production and growth: identity of colony-stimulating factor and 
macrophage growth factor. J. Exp. Med 143, 631-647 (1976). 
114. Kwon, B. et al. Identification of a novel activation-inducible protein of the tumor 
necrosis factor receptor superfamily and its ligand. J. Biol. Chem 274, 6056-6061 
(1999). 
115. Schadt, E.E., Li, C., Su, C. & Wong, W.H. Analyzing high-density oligonucleotide 
gene expression array data. J. Cell. Biochem 80, 192-202 (2000). 
116. Ashburner, M. et al. Gene ontology: tool for the unification of biology. The Gene 
Ontology Consortium. Nat. Genet 25, 25-29 (2000). 
117. Phinney, D.G. & Prockop, D.J. Concise review: mesenchymal stem/multipotent 
stromal cells: the state of transdifferentiation and modes of tissue repair--current 
views. Stem Cells 25, 2896-2902 (2007). 
118. Meirelles, L.D.S. & Nardi, N.B. Murine marrow-derived mesenchymal stem cell: 
isolation, in vitro expansion, and characterization. Br. J. Haematol 123, 702-711 
(2003). 
119. Bonney, R.J. et al. Regulation of prostaglandin synthesis and of the selective release 
of lysosomal hydrolases by mouse peritoneal macrophages. Biochem. J 176, 433-
442 (1978). 
120. Tsuji, S. et al. Evidences for involvement of cyclooxygenase-2 in proliferation of 
two gastrointestinal cancer cell lines. Prostaglandins Leukot. Essent. Fatty Acids 55, 
179-183 (1996). 
121. Shibolet, O. & Podolsky, D.K. TLRs in the Gut. IV. Negative regulation of Toll-like 
receptors and intestinal homeostasis: addition by subtraction. Am. J. Physiol. 
Gastrointest. Liver Physiol 292, G1469-1473 (2007). 
122. Takeda, K. & Akira, S. Toll-like receptors in innate immunity. Int. Immunol 17, 1-
14 (2005). 
123. Doherty, J.M., Geske, M.J., Stappenbeck, T.S. & Mills, J.C. Diverse adult stem cells 
share specific higher-order patterns of gene expression. Stem Cells 26, 2124-2130 
(2008). 
124. Geske, M.J., Zhang, X., Patel, K.K., Ornitz, D.M. & Stappenbeck, T.S. Fgf9 
 103
signaling regulates small intestinal elongation and mesenchymal development. 
Development 135, 2959-2968 (2008). 
125. Ornitz, D.M. et al. Receptor specificity of the fibroblast growth factor family. J. 
Biol. Chem 271, 15292-15297 (1996). 
126. Ornitz, D.M. & Itoh, N. Fibroblast growth factors. Genome Biol 2, REVIEWS3005 
(2001). 
127. Zhang, X. et al. Reciprocal epithelial-mesenchymal FGF signaling is required for 
cecal development. Development 133, 173-180 (2006). 
128. Eswarakumar, V.P., Lax, I. & Schlessinger, J. Cellular signaling by fibroblast 
growth factor receptors. Cytokine Growth Factor Rev 16, 139-149 (2005). 
129. Itoh, N. & Ornitz, D.M. Functional evolutionary history of the mouse Fgf gene 
family. Dev. Dyn 237, 18-27 (2008). 
130. Colvin, J.S., White, A.C., Pratt, S.J. & Ornitz, D.M. Lung hypoplasia and neonatal 
death in Fgf9-null mice identify this gene as an essential regulator of lung 
mesenchyme. Development 128, 2095-2106 (2001). 
131. Weaver, M., Dunn, N.R. & Hogan, B.L. Bmp4 and Fgf10 play opposing roles 
during lung bud morphogenesis. Development 127, 2695-2704 (2000). 
132. ten Berge, D., Brugmann, S.A., Helms, J.A. & Nusse, R. Wnt and FGF signals 
interact to coordinate growth with cell fate specification during limb development. 
Development 135, 3247-3257 (2008). 
133. Sala, F.G. et al. Fibroblast growth factor 10 is required for survival and proliferation 
but not differentiation of intestinal epithelial progenitor cells during murine colon 
development. Dev. Biol 299, 373-385 (2006). 
134. Petiot, A. et al. A crucial role for Fgfr2-IIIb signalling in epidermal development 
and hair follicle patterning. Development 130, 5493-5501 (2003). 
135. Lin, Y. et al. Neuron-derived FGF9 is essential for scaffold formation of Bergmann 
radial fibers and migration of granule neurons in the cerebellum. Dev. Biol 329, 44-
54 (2009). 
136. Inagaki, T. et al. Fibroblast growth factor 15 functions as an enterohepatic signal to 
regulate bile acid homeostasis. Cell Metab 2, 217-225 (2005). 
137. Ben-Dov, I.Z. et al. The parathyroid is a target organ for FGF23 in rats. J. Clin. 
Invest 117, 4003-4008 (2007). 
138. Razzaque, M.S. FGF23-mediated regulation of systemic phosphate homeostasis: is 
Klotho an essential player? Am. J. Physiol. Renal Physiol 296, F470-476 (2009). 
139. Estívariz, C.F. et al. Regulation of keratinocyte growth factor (KGF) and KGF 
receptor mRNAs by nutrient intake and KGF administration in rat intestine. Dig. 
Dis. Sci 45, 736-743 (2000). 
140. Kage, K. et al. Basic fibroblast growth factor induces cyclooxygenase-2 expression 
in endothelial cells derived from bone. Biochem. Biophys. Res. Commun 254, 259-
263 (1999). 
141. Pham, H., Chong, B., Vincenti, R. & Slice, L.W. Ang II and EGF synergistically 
induce COX-2 expression via CREB in intestinal epithelial cells. J. Cell. Physiol 
214, 96-109 (2008). 
142. Cao, Z. et al. Insulin-like growth factor-I induces cyclooxygenase-2 expression via 
PI3K, MAPK and PKC signaling pathways in human ovarian cancer cells. Cell. 
Signal 19, 1542-1553 (2007). 
 104
143. Stoeltzing, O. et al. Regulation of cyclooxygenase-2 (COX-2) expression in human 
pancreatic carcinoma cells by the insulin-like growth factor-I receptor (IGF-IR) 
system. Cancer Lett 258, 291-300 (2007). 
144. Anant, S. et al. Apobec-1 protects intestine from radiation injury through 
posttranscriptional regulation of cyclooxygenase-2 expression. Gastroenterology 
127, 1139-1149 (2004). 
145. Mason, I. Initiation to end point: the multiple roles of fibroblast growth factors in 
neural development. Nat. Rev. Neurosci 8, 583-596 (2007). 
146. Yaksh, T.L. et al. The acute antihyperalgesic action of nonsteroidal, anti-
inflammatory drugs and release of spinal prostaglandin E2 is mediated by the 
inhibition of constitutive spinal cyclooxygenase-2 (COX-2) but not COX-1. J. 
Neurosci 21, 5847-5853 (2001). 
147. Zimmermann, K.C., Sarbia, M., Schrör, K. & Weber, A.A. Constitutive 
cyclooxygenase-2 expression in healthy human and rabbit gastric mucosa. Mol. 
Pharmacol 54, 536-540 (1998). 
148. Williams, C.S., Mann, M. & DuBois, R.N. The role of cyclooxygenases in 
inflammation, cancer, and development. Oncogene 18, 7908-7916 (1999). 
149. Wang, J. & Hauer-Jensen, M. Neuroimmune interactions: potential target for 
mitigating or treating intestinal radiation injury. Br J Radiol 80 Spec No 1, S41-48 
(2007). 
150. Kiba, T. Relationships between the autonomic nervous system, humoral factors and 
immune functions in the intestine. Digestion 74, 215-227 (2006). 
151. Ogawa, K., Funaba, M., Chen, Y. & Tsujimoto, M. Activin A functions as a Th2 
cytokine in the promotion of the alternative activation of macrophages. J. Immunol 
177, 6787-6794 (2006). 
152. Robson, N.C. et al. Activin-A: a novel dendritic cell-derived cytokine that potently 
attenuates CD40 ligand-specific cytokine and chemokine production. Blood 111, 
2733-2743 (2008). 
153. Raskovalova, T. et al. Gs protein-coupled adenosine receptor signaling and lytic 
function of activated NK cells. J. Immunol 175, 4383-4391 (2005). 
154. Grbic, D.M., Degagné, E., Langlois, C., Dupuis, A. & Gendron, F. Intestinal 
inflammation increases the expression of the P2Y6 receptor on epithelial cells and 
the release of CXC chemokine ligand 8 by UDP. J. Immunol 180, 2659-2668 (2008). 
155. Kavic, S.M. & Basson, M.D. Complications of endoscopy. Am. J. Surg 181, 319-
332 (2001). 
156. Touzios, J.G. & Dozois, E.J. Diverticulosis and acute diverticulitis. Gastroenterol. 
Clin. North Am 38, 513-525 (2009). 
157. Schumert, R., Nast, C.C., Cominelli, F. & Zipser, R.D. Effects of 16,16-dimethyl 
prostaglandin E2 and indomethacin on leukotriene B4 and inflammation in rabbit 
colitis. Prostaglandins 36, 565-577 (1988). 
158. Ballinger, A. Adverse effects of nonsteroidal anti-inflammatory drugs on the colon. 
Curr Gastroenterol Rep 10, 485-489 (2008). 
159. Ule, J., Jensen, K., Mele, A. & Darnell, R.B. CLIP: a method for identifying 
protein-RNA interaction sites in living cells. Methods 37, 376-386 (2005). 
160. Becker, C. et al. TGF-beta suppresses tumor progression in colon cancer by 
inhibition of IL-6 trans-signaling. Immunity 21, 491-501 (2004). 
 105
161. Becker, C. et al. In vivo imaging of colitis and colon cancer development in mice 
using high resolution chromoendoscopy. Gut 54, 950-954 (2005). 
162. Walker, M.R., Brown, S.L., Riehl, T.E., Stenson, W.F. & Stappenbeck, T.S. Growth 
factor regulation of prostaglandin-endoperoxide synthase 2 (Ptgs2) expression in 
colonic mesenchymal stem cells. J. Biol. Chem 285, 5026-5039 (2010). 
163. Sorrell, J.M. & Caplan, A.I. Fibroblasts-a diverse population at the center of it all. 
Int Rev Cell Mol Biol 276, 161-214 (2009). 
164. Andreasson, K. Emerging roles of PGE2 receptors in models of neurological disease. 
Prostaglandins Other Lipid Mediat 91, 104-112 (2010). 
165. Radi, Z.A. Pathophysiology of cyclooxygenase inhibition in animal models. Toxicol 
Pathol 37, 34-46 (2009). 
166. Collins, L.J., Kurland, C.G., Biggs, P. & Penny, D. The modern RNP world of 
eukaryotes. J. Hered 100, 597-604 (2009). 
167. Anant, S. & Houchen, C.W. HuR and TTP: two RNA binding proteins that deliver 
message from the 3' end. Gastroenterology 136, 1495-1498 (2009). 
168. Hao, S. & Baltimore, D. The stability of mRNA influences the temporal order of the 
induction of genes encoding inflammatory molecules. Nat. Immunol 10, 281-288 
(2009). 
169. Weidensdorfer, D. et al. Control of c-myc mRNA stability by IGF2BP1-associated 
cytoplasmic RNPs. RNA 15, 104-115 (2009). 
170. Sureban, S.M. et al. Translation regulatory factor RBM3 is a proto-oncogene that 
prevents mitotic catastrophe. Oncogene 27, 4544-4556 (2008). 
171. Vlasova, I.A. et al. Conserved GU-rich elements mediate mRNA decay by binding 
to CUG-binding protein 1. Mol. Cell 29, 263-270 (2008). 
172. Ishikawa, T. & Herschman, H.R. Conditional knockout mouse for tissue-specific 
disruption of the cyclooxygenase-2 (Cox-2) gene. Genesis 44, 143-149 (2006). 
173. Watanabe, J. et al. Novel anti-inflammatory functions for endothelial and myeloid 
cyclooxygenase-2 in a new mouse model of Crohn's disease. Am. J. Physiol. 
Gastrointest. Liver Physiol 298, G842-850 (2010). 
 
